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Abstract
Holli-Joi Sullivan
AN IN SILICO STUDY OF SMALL MOLECULE ANTI-CANCER AGENTS
TARGETING DNA G-QUADRUPLEXES
2019-2020
Chun Wu, Ph.D.
Master of Science in Pharmaceutical Sciences

Free ligand binding molecular dynamic simulations are a powerful tool used to
probe the ligand binding process, mechanism and pathway and the insight gained can
help expedite the early stages of drug discovery. Using these methods, we model the
binding of two small molecule anti-cancer agents BRACO19 and CX-5461 to a variety of
DNA G-quadruplexes (G4s) and a DNA Duplex. The first study focuses on the binding
of BRACO19 to three different topological folds (parallel, anti-parallel and hybrid) of the
human telomeric G4s. Our detailed analysis identified the most stable binding modes
were end stacking and groove binding for the G4s and duplex, respectively. With the
parallel scaffold being most favorable, we suggest a conformation-selection mechanism
where the relative population of the three scaffolds shifts to an increase of the parallel
scaffold upon BRACO19 binding. The second study focuses on the binding of CX-5461
to human telomeric, c-KIT1, and c-Myc G4s. Our analysis was able to provide insight
into a FRET-melting temperature increase assay measured the stabilizing effects of CX5461 to each of these targets. The energetic and structural differences explained the
different melting temperature between the G4s, while CX-5461’s lack of intercalation to
the duplex explained the difference between the G4s and duplex. Using our insight CX5461 derivatives were deigned and docked with higher selectivity to the G4s over the
duplex, which might aid in further optimization of CX-5461.
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Chapter 1
Introduction to Free Ligand Molecular Dynamics Simulation and Its Application to
Computer-Aided Drug Design
1.1 Motivations for a Computational Approach
Many questions exist regarding the role of biological molecules in human health
and diseases. For example, why does one medication work better than another? How
does a medication interact with the intended target? Can this medication interact with
other targets? How can we quantify the binding of this medication to its target? For
decades, the focus of many medicinal chemists has been attempting to provide
answers to these fundamental questions. It is by answering these questions that
researchers are able to identify and optimize small molecules for therapeutic use that
selectively target pharmacologically relevant human diseases such as cancer,
neurodegenerative disorders, and diabetes.
Notwithstanding the assiduous efforts of researchers, traditional development
methods of a new medication is a costly and labor intensive process. From the initial
identification phase until the approval for marketing is 14 years on average and costs
between 2-3 billion dollars1, 2. Despite the unprecedented investments into
pharmaceutical research and development from 1950 to 2008, the US Food and Drug
Administration (FDA) approved just 1,222 new drugs averaging ~21 new drugs put
on the market per year. Interestingly, around 2010 there were reports of large
pharmaceutical companies beginning to use computational approaches in their
discovery pipelines3 and since then the number of new drugs put on the market has
increased from 21 in 2008 to 59 in 20184.
1

By use of a computational approach, researchers are able to address the same
fundamental questions regarding the role of biological molecules in human health and
diseases on a much shorter timeframe and cost basis. The insight gained from these
studies have a broad range of applications but has been specifically useful for
pharmaceutical drug discovery. Computer-aided drug design (CADD) couples
molecular modeling methods with molecular dynamics simulations for drug design.
CADD tools are powerful and have had much success since the initial integration into
the drug discovery pipeline. Visualization tool such as those implemented through
VMD and Maestro are used to visualize high resolution coordinates solved by x-ray
crystallography or nuclear magnetic resonance. The increased computational
resources available enable molecular dynamics simulations programs such as Amber
and Desmond to predict detailed atomic level insight into molecular process,
mechanism and dynamics on the nanosecond to millisecond timescale5, 6.
For example, an early computational approach to studying ligand binding was
through the use of docking. Docking is an indispensable, fast and cost efficient
method to predict the bound conformations of small molecule ligands to their
pharmacologically relevant targets7. Understanding the binding conformation of a
small molecule ligand is an important feature in structure-based drug design where
the three-dimensional structural information is used to predict the key sites and
interactions of the ligand and its target which can be used for rational drug design.
Due to the quick and computational uncostly nature of docking, it can be extremely
convenient for screening large libraries of molecules. However, docking does not
capture the dynamics of the binding process and only provides a final binding pose.
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This can be a disadvantage for studying ligand binding because the process is highly
dynamic.
This limitation of docking was partially addressed through the introduction of
molecular dynamics (MD) simulations to the field. MD is a computational technique
used to simulate the dynamic behavior of molecular systems as over time. By using
the docking pose or an experimentally solved binding pose, as the starting position,
conventional MD simulations can be coupled with molecular docking to assess
stability, refine the structures of the final complexes and rescore and calculate more
detailed interaction energies of the docking poses8. This approach provides another
level of dynamic insight, however it the result relies on the position of the ligand in
the initial binding pose. Thus, the detailed and dynamic binding pathway and binding
process still cannot be probed in full.
Free ligand molecular dynamics simulations are able to model the binding process
of a small molecule starting from the unbound state without a rigid body assumption.
Using a high temperature to randomize the initial position of the ligand, plus long
time simulation, the phase space of a molecular system can be well sampled.
Although this method is more costly in terms of time and computation, free ligand
molecular dynamics binding simulations are more accurate and are able to predict the
major binding site, ligand binding pose, detailed binding interactions, major driving
force for ligand binding, binding affinity and energy, and even the binding pathway.
Because neither the target or ligand are forced to be rigid during the ligand binding
process, dynamic binding mechanisms are able to be observed like the induced fit and
conformational-selection mechanisms. This is extremely important because ligands
3

often bind to their targets using a dynamic mechanism rather than the lock-key
mechanism. Even more, new ligand binding sites are often identified using this
method, including high energy intermediate states, which are hard to study using
experimental methods. Which is why the insights from the simulations can be very
useful for structure based drug design, improve ligand binding and often helps guide
lead optimization.
Free ligand molecular dynamics simulations are able to model the binding process
of a small molecule starting from the unbound state without a rigid body assumption.
Using a high temperature to randomize the initial position of the ligand, plus long
time simulation, the phase space of a molecular system can be well sampled.
Although this method is more costly in terms of time and computation, free ligand
molecular dynamics binding simulations are more accurate and are able to predict the
major binding site, ligand binding pose, detailed binding interactions, major driving
force for ligand binding, binding affinity and energy, and even the binding pathway.
Because neither the target or ligand are forced to be rigid during the ligand binding
process, dynamic binding mechanisms are able to be observed like the induced fit and
conformational-selection mechanisms. This is extremely important because ligands
often bind to their targets using a dynamic mechanism rather than the lock-key
mechanism. Even more, new ligand binding sites are often identified using this
method, including high energy intermediate states, which are hard to study using
experimental methods. Which is why the insights from the simulations can be very
useful for structure based drug design, improve ligand binding and often helps guide
lead optimization.

4

1.2

Motivations for Studying DNA G-Quadruplexes

DNA G-Quadruplexes (G4s) are secondary structures of nucleic acids formed by
sequences that are rich in guanine. In terms of structure, when four of these guanine
bases interact through hydrogen bonding they form a G-tetrad and when three gtetrads stack on top of each other they form the G4 core which is stabilized by cations
like potassium. Then to complete the structure, short 1-5 residue loops connect each
g-quartet and it is the connection of these loops that defines the overall topology of
the G4. The different structures are characterized into three major interconverting
topologies which are parallel, anti-parallel, and hybrid. In the parallel structure the
connecting loops are proceed in the same direction, where as the anti-parallel
structure has each loop adopting the opposite configuration as the one that came
before it, and in the hybrid structure there is a mixture of both.
In terms of locations in the body, these G4s are spontaneously formed in two
major guanine rich regions. The first is at the end of the chromosome in the telomeres
and the second is in the promoter region of oncogenes. As for the telomeric G4s, in
normal cells, the telomeres shorten over time and cell division stops, however in
cancerous cells, telomerase facilitates the process of replacing the shortened telomere.
Essentially, telomerase is a reverse transcriptase enzyme that adds repeat segments to
the 3’ end of telomeric DNA, and because telomerase is highly expressed in almost
all cancers, the segments added are often sequences that contain a cancerous mutation
and the cells ultimately form a malignant tumor. Therefore, the major anticancer
approach for targeting telomeric G4’s is to stabilize the G4s using a ligand to prevent
telomerase from functioning.

5

The promoter G4s are found is the promoter region of oncogenes throughout the
chromosome. Some of these oncogenes include c-KIT, PDGF-A, c-Myc and VEGF.
For example, the c-myc pathway plays an integral role in regulating c-Myc. This is a
protein product and with this, the c-Myc protein functions in the processes of
apoptosis, cell growth, and for transcriptional control on human telomerase reverse
transcriptase. This is just one example of how the structures are formed in essential
genes, which really highlights the importance of this secondary structure in the
development and growth of cancerous cells. Much like the telomeric G4s, the
therapeutic approach for promoter G4s is also to stabilize the G4 using a ligand, but
in this case, stabilizing the G4 can help prevent the transcription of the gene that
contains a cancerous mutation. While the formation of G-quadruplex structure vary to
some extent for the different promoter regions of oncogenes, the consistent
stabilization of these structures have been found in cancer development.
These structures are very prosing anti-cancer targets because they are more diverse
and stable than the DNA duplex and over 300,000 sequence motifs have been
identified within the human genome. However in order to target these structures,
there are several major challenges that need to be overcome which is why there are no
G4 stabilizers on the market to date. Specifically, the major challenge is that there is
a low potency and a lack of selectivity to G4s over the duplex structure. Like many
classes of medications, without the selectivity to the major target, adverse effects can
be observed. Which is why improvements are needed. However, it has become
difficult to make improvements to this class of drug without understanding the
detailed binding mechanism. So in order to best utilize these promising structures for
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their anticancer effects, the binding mechanism of the G4 stabilizers must first be
understood.
1.3 Computational Methodologies
1.3.1 Molecular docking and structure based virtual screening. Molecular
docking is an indispensable, fast and cost efficient method to predict the binding
pose of small molecule ligands to their pharmacologically relevant targets and has
been extremely convenient for screening large libraries of molecules. Molecular
docking has been utilized in combination with structure-based virtual screening (VS)
for drug discovery for over a decade to automatically dock of large libraries of
ligands into a target in a relatively a short amount of time. The docking poses are
achieved by using software that generates a molecular surface of the target structure
based on high resolution structures. Using a known ligand binding site, the software
generates spheres in the binding site and these spheres match with the new ligands to
determine all possible orientations. Then the software will use a scoring function to
rank each possible binding pose where a higher score indicates a more favorable
binding. There are three major scoring functions that can be used. First, the forcefield based approach uses physical-based functional forms based on experimental
data to estimate binding affinity. Second, empirical scoring simplifies the parameters
of the first approach to approximate favorable interactions, which is much faster but
slightly less accurate. The third approach is knowledge-based scoring functions
derived from known binding interactions and expected to be more common than by
random distribution. Following the scoring functions, and especially useful in
structure based virtual screenings, ADME (absorption, distribution, metabolism,
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excretion) property prediction software can be utilized to provide insight into a wide
range of pharmaceutically relevant properties about a molecule’s suitability and
druggability, such as octanol/water and water/gas log Ps, log S, and log BB. Because
roughly 40% of all potential medications fail clinical trials due to poor ADME
properties, early prediction is extremely cost and time effective and can prevent
unnecessary testing of compounds that are likely to ultimately fail. In this study, we
utilized Schrodinger’s Glide docking program using extra precision which is a semi
empirical scoring function utilizing water desolvation energy terms followed by their
QikProp ADME prediction software.

XP Glide Score = ΔEcoul + ΔEvdW+Ebind +Epenalty
Ebind=Ehyd_enclosure4+Ehb_nn_motif5 +Ehb_cc_motif6 +EpI7 + Ehb_pair +Ephobic_pair
Epenalty = Edesolv +Eligand_strain

1.3.2 Molecular dynamics simulations. Molecular dynamics is a computational
simulation method used to analyze the physical movements of atoms and molecules.
Essentially, molecular dynamics simulations are able to mimic what atoms do in real life,
based on a given potential energy function which is used to calculate the force
experienced by any atom given the positions of the other atoms in the model system. The
atoms and molecules are allowed to interact for a fixed period of time, giving a view of
the dynamic evolution of the system. Then, by using Newton’s Second Law, molecular
dynamics simulations predict how the forces will affect the motions of the atoms. Thus
probing the position and velocity of particles within a given system that when paired with
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the structure gives a complete analysis of the interaction dynamics of the model system at
high spatial and temporal resolution.
More specifically, the aforementioned forces calculated in a molecular dynamics
simulation are based on what is a called a force field, a set of parameters to define the
potential energy function of a molecular system. The parameters include both bonded and
nonbonded interactions amongst the atoms in the model system. The bonded interactions
are comprised of bond, angle and dihedral angles and the nonbonded interaction are the
van der Waals and electrostatic interactions within the model system. Within this system,
further coupling parameters are set to maintain a constant pressure and temperature. Two
types of solvent models can be used to realistically model the interactions between the
solvent and the solute molecules, which are called implicit and explicit solvent models.
The implicit solvent model treats a solvent as one continuous medium using a dielectric
constant, whereas the explicit solvent model uses thousands of solvent molecules.
Although the explicit model can produce more accurate results when comparing systems
that are highly variable from each other, due to the higher computational cost, an implicit
model may be used as a fair alternative for systems that are more closely comparable.
Once the system is prepared, the molecular dynamic simulation is run on this
system until an equilibrium state is reached. Using snap shots from the simulation a time
progression is generated and used to generate the simulation trajectory. Each snapshot
contained coordinates that specify the position of atoms in the system. From the
trajectory, a number of post simulation analyses can be performed including a trajectory
clustering. One method for this is a through a pairwise comparison which is done by first
aligning each snapshot from the trajectory of the ligand-target complex. Once aligned, the
9

structures can be clustered into unique structural families based on the root mean square
deviations (RMSD) of their atomic positions and the larger structural families can be
identified as the most prevalent binding positions for the system.
1.3.3 Markovian state modeling. Markov State Models (MSMs) can be built
from molecular dynamics simulation data and are a comprehensive statistical approach
used to create understandable yet high-resolution models of the intrinsic kinetics of a
system. In order to build the MSM microstates are built. To do this, the trajectories are
first subjected to a clustering method, K-means clustering, which differs from the
pairwise clustering method described above. Where pairwise clustering examines each
pair of N structures, K-means defines a number of clusters and assigns structures to each
cluster based on the relative similarity to the mean structure of each cluster. K-means
clustering is a rapid clustering method able to exponentially scale with N, but the tradeoff for speed is the level of accuracy delivered using this method. For the K-means
clustering in this study, two features were used for the calculation, RMSD and center of
mass. Center of mass was included because we observe the ligand bound in a near
spherical cloud around the G-quadruplex, the RMSD values could overlap with RMSD
values of ligands at the opposite ends of the cloud. By incorporating center of mass, the
level of accuracy was maintained while reducing the time for the clustering to complete
from days to minutes. Due to choosing to cluster into a handful of “macrostates” and
directly and skipping over the experimentally unverifiable thousand “microstates”, the
expected convergence time of the implied timescales should be significantly greater than
that of a model with a greater number of clusters. This results in a coarser grained model
that trades finer detail for greater experimental testability and easier human
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understanding. It is likely that directly clustering into “macrostates” still maintains the
integrity of the MSM as verification through the Chapman-Kolmogorov test indicates
that the model closely resembles the observed simulation data. Since a key feature of
MSMs is that they are memoryless, the current state predicts the future state without
knowing the past state. In terms of the kinetic insight this analysis can provide, the major
result is the percentage of each state and the mean transition times between the major
binding modes. The implied time method or the Chapman-Kolmogorov test is typically
used to determine the lag time for counting the transitions. Once transition matrix is
obtained, the mean passage time between states can be calculated.
1.3.4 MMGBSA/MMPBSA binding energy calculations. Quantifying the binding
free energy of a ligand to its target is extremely useful in understanding its stability, and
binding favorability to one binding site versus another. Of the binding free energy
prediction methods, end point methods have been extremely useful when calculating the
binding free energies of the unbound and bound states of a model system. Of the end
point methods are the molecular mechanics generalized Born surface area (MM-GBSA)
and molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) methods. These
methods allow for energy decomposition into the following components: electrostatic,
van der Waals, and hydrophobic interaction using surface area term. The calculations are
performed on the receptor alone through minimization, on the ligand alone, and finally,
the ligand target complex is calculated. The final output of these calculations contain the
contribution of each component on the total binding energy which provides quantitative
insight into the most favorable binding mode. Although these calculations are extremely
useful in making general predictions and orders of stability, because the calculation does
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not include a solute entropy, the reported energy could be an over-estimation of the true
binding free energy. However, this is overcome relatively when the solute conformational
entropies in different binding poses are comparable to one another and thus the relative
binding free energy can be estimated relative to the MMGBSA binding energies. MMPBSA9 (Molecular Mechanics Poisson Boltzmann Surface Area) was used to analyze the
energetics of the bound complexes. The MM-PBSA binding energy for a system was
calculated based on three simulations: the ligand only, the DNA only and the DNAligand complex using equation 1. The equation is made of four components, equation 2:
van der Waals interaction energy (VDW), hydrophobic interaction energy (SUR),
electrostatic interaction (GBELE) and the change of the conformation energy for DNA
and ligand which are calculated using equation 3 and 4.
Eq 1:

∆𝐸 = 𝐸𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝐷𝑁𝐴_𝑓𝑟𝑒𝑒 − 𝐸𝑙𝑖𝑔_𝑓𝑟𝑒𝑒

Eq 2:

∆𝐸 = ∆𝐸𝑣𝑑𝑤 + ∆𝐸𝑆𝑈𝑅 + ∆𝐸𝐺𝐵𝐸𝐿𝐸 + ∆𝐸𝑐𝑜𝑚𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛

Eq 3:

∆𝐸𝑥 = 𝐸𝑥_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑥_𝐷𝑁𝐴_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑥_𝑙𝑖𝑔_𝑐𝑜𝑚𝑝𝑙𝑒𝑥
x= vdw, sur and gbele

Eq 4:

∆𝐸𝐶𝑜𝑚𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 = 𝐸𝐷𝑁𝐴_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 +𝐸𝑙𝑖𝑔_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝐷𝑁𝐴_𝑓𝑟𝑒𝑒 − 𝐸𝑙𝑖𝑔_𝑓𝑟𝑒𝑒

1.4 Thesis Outline
In Chapter 2, the binding pathway of BRACO19 was probed by 27.5 µs molecular
dynamics binding simulations with a free ligand to a DNA duplex and three different
topological folds of the human telomeric DNA G-quadruplex (parallel, anti-parallel and
hybrid). BRACO19 is a potent G-quadruplex binder, but its potential for clinical usage is
hindered by its low selectivity towards DNA G-quadruplex over duplex. High-resolution
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structures of BRACO19 in complex with neither single-stranded telomeric DNA Gquadruplexes nor B-DNA duplex are available, thus the detailed interactions of
BRACO19 to these targets remain elusive. Our analyses probed these interactions and
showed that the most stable binding modes were identified as end stacking and groove
binding for the DNA G-quadruplexes and duplex, respectively. Among the three Gquadruplex topologies, the MM-GBSA binding energy analysis suggested that
BRACO19′s binding to the parallel scaffold was most energetically favorable. We
deciphered two lines of conflicting evidence, along with our binding energy data, to
suggest a conformation-selection mechanism is used where the relative population shift
of three scaffolds upon BRACO19 binding. Or in other words, there is an increase of the
population of the parallel scaffold, and a decrease of populations of antiparallel and/or
hybrid scaffolds. This hypothesis appears to be consistent with the fact that BRACO19
was specifically designed based on the structural requirements of the parallel scaffold and
has since proven effective against a variety of cancer cell lines as well as toward a
number of scaffolds. In addition, this binding mode is only slightly more favorable than
BRACO19s binding to the duplex, explaining the low binding selectivity of BRACO19
to G-quadruplexes over duplex DNA. Our detailed analysis suggests that BRACO19′s
groove binding mode may not be stable enough to maintain a prolonged binding event
and that the groove binding mode may function as an intermediate state preceding a more
energetically favorable end stacking pose. Finally we observed that base flipping played
an important role in enhancing binding interactions which is an integral feature of an
induced fit binding mechanism. In Chapter 3, we study the binding interactions of DNA
G-quadruplex (G4) stabilizer, CX-5461, to human telomeric, c-KIT1, and c-Myc G4
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structures as well as a DNA duplex. CX-5461 is in Phase I/II clinical trials for advanced
hematologic malignancies and cancers with BRCA1/2 deficiencies. Recently, a FRETmelting temperature increase assay measured the stabilizing effects of 10 µM CX-5461 to
canonical DNA duplex (~10 K) and three G4 forming sequences negatively implicated in
BRCA1/2 mutations upon its binding: human telomeric (~30 K), c-KIT1 (~27 K) and cMyc (~25 K). Without experimentally solved structures of these CX-5461-G4 complexes,
CX-5461’s binding interactions remain elusive. To probe these interactions, we
performed 16.5 µs free ligand molecular dynamics binding simulations of CX-5461 to the
DNA duplex and three G4s. Our analyses detailed their thermodynamic, kinetic, and
structural nature at the molecular level. CX-5461’s average MM/PBSA of the major
poses were calculated for the human telomeric (-28.6 kcal/mol), c-KIT1 (-23.9 kcal/mol),
c-Myc (-22.0 kcal/mol) G4s, and DNA duplex (-15 kcal/mol) systems. These energetic
differences coupled with structural differences at the 3’ site explained the different
melting temperature between the G4s, while CX-5461’s lack of intercalation to the
duplex explained the difference between the G4s and duplex. CX-5461 derivatives were
deigned and docked with higher selectivity to the G4s over the duplex, which might aid
in further optimization of CX-5461.
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Chapter 2
Binding of BRACO19 to a Telomeric G-Quadruplex DNA Probed by All-Atom
Molecular Dynamics Simulations with Explicit Solvent
2.1 Introduction
2.1.1 Human telomeric G-quadruplex DNA. The first therapeutically important
G-quadruplex sequence was located in the single stranded 3’ overhang of human
telomeric DNA 10, 11, and contains numerous repeats of d(TTAGGG)n sequences capped
by Shelterin complexes 12-15. The Shelterin complexes provide protection against
nuclease attacks, chromosomal end-to-end fusion and gene erosion at cell divisions 16.
After each cell replication the telomere truncates by 50-200 base pairs, when the telomere
is exhausted and the Hayflick limit is reached. This hayflick limit essentially states that a
normal human cell can only replicate and divide forty to sixty times before it cannot
divide anymore, and will break down by programmed cell death or apoptosis thus cell
senescence and apoptosis are triggered 17, 18. In cancer cells, a reverse transcriptase
telomerase adds nucleotides to the telomere, immortalizing the cells 19, 20. Telomerase is
found to be overexpressed in 80-85% of tumor cells underscoring why telomerase
inhibition is a logical therapeutic approach in cancer treatment. Despite the potential of
this approach challenges include: (i) a time delay in which the telomere length needs to
be established for the ultimate apoptosis trigger 17, 21, 22 and (ii) that studies suggest an
alternate mechanism for telomerase maintenance might be activated upon telomerase
inhibition 23-25. However, it has been reported that the telomere cannot be hybridized by
telomerase when the single stranded 3’ overhang folds into a G-quadruplex 26, instead the
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telomeric G-quadruplex is perceived as DNA damage and stimulates cell level apoptosis
11, 27

. Accentuating how a ligand that stabilizes the telomeric G-quadruplex can be an

efficacious anti-cancer therapy.
2.1.2 Topological folds of the human telomeric G-quadruplex DNA. Extensive
research has been performed that show G-quadruplexes are highly polymorphic and their
topological fold depends on factors such as nucleic acid sequence, ions and the presence
of small molecules

28-32

. Though studied for decades, the most biologically relevant

topological fold of human telomeric G-quadruplex remains an elusive and controversial
debate. In 1993, Wang and Patel published the first solution structure of the human
telomeric sequence d[AG3(T2AG3)3] in Na+ containing solution which adopts anti-parallel
topology (PDB ID: 143D); formally referred to as 3(-lwd+ln)33. In 2002, Parkinson and
coworkers published a K+-containing crystal structure of the human telomeric DNA in a
parallel topological fold, referred to as 3(-p-p-p) using the nomenclature recently described
by Dvorkin et al.34 (PDB ID: 1KF1)35. The parallel crystal structure published by Parkinson
and coworkers was different from the preceding studies which reported the DNA in an antiparallel topological fold in Na+ containing solution

33, 36, 37

. In the years following,

experiments providing evidence for both topological folds continued to publish. The
parallel topological fold was suggested the most biologically relevant form in K+
containing crystal because the polymorphism of the G-quadruplex structure was lost in
40% PEG or 50% ethanol solutions, i.e., dehydrated solutions38. Heddi and Phan studied
the human telomeric sequence under crowded conditions with NMR, using the same
dehydrating crowding agents used in X-ray crystallography, and found that the parallel
conformation predominated

39

. In contrast, solution studies using NMR and
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125

I-

radioprobing were also published providing evidence for the anti-parallel topology in both
K+- and Na+-containing solution, several of which reported the parallel and anti-parallel
topologies coexist under both ionic conditions

40-43

.

Not long after Parkinson and

coworker’s parallel crystal structure was published solution studies began to identify
additional topological folds for the human telomeric DNA44-48. Yang and coworkers

49

showed the same sequence with two additional naturally occurring adenine residues at the
5’ and 3’ termini in K+ solution folds into a hybrid scaffold in 2007 (PDB ID: 2HY9),
formally referred to as 3(-p-lw-ln). The skepticism regarding the predominating topology
in physiological conditions has led to studies suggesting that rather than the parallel
topology, both the anti-parallel

43, 50, 51

and hybrid

45, 49

forms are most physiologically

relevant.
The contradicting results being published gave rise to discussion regarding the
experimental accuracy of using dehydrating crowding agents like PEG to report the
structure of the highly flexible and dynamic DNA G-quadruplex. In 2005, Li and
coworkers published work that directly refuted the biological relevance of the parallel
stranded crystal structure of the human telomeric DNA G-quadruplex reported by
Parkinson and coworkers delineating that by using certain dehydrating solvents, like PEG,
crowding conditions are not being mimicked but rather conditions of extreme water
depletion that is misrepresentative of physiological conditions. 28, 50 Using acetylnitrile, a
non-dehydrating crowding agent, Miller et al. proposed the structure of the human
telomeric sequence was not identical to the structure published in crystalline state,
supporting the role of hydration in the stability and conformation of this human telomeric
sequence. Using Ficoll and Xenopus laevis egg extract compared to PEG, Hansel and

17

coworkers suggested the parallel scaffold is not the preferred topology under physiological
conditions, but rather the parallel, anti-parallel, and hybrid topologies co-exist under native
conditions. Stating that in Ficoll or cellular extracts, the more predominate conformations
in the co-existing equilibrium mixture are likely the anti-parallel and/or the hybrid
topologies. Analyzing the studies overall, evidence suggests that this sequence forms
multiple intramolecular G-quadruplex scaffolds in K+ solution and the intramolecular
parallel G-quadruplex observed in the K+-containing crystal appears unlikely to be the
major form in K+- containing solution41, 42, 52-56. Given the broad range of evidence to
support each of the three scaffolds and without evidence to rule out the predominance of
any of the reported scaffolds, one of each the parallel, anti-parallel, and hybrid topological
folds were modeled in this study.
2.1.3 Anti-cancer agent BRACO19. Based on structural requirements of the
parallel-stranded telomeric G-quadruplex binding site, BRACO19, a tri-substituted
acridine, was rationally designed with computer modelling 57, 58 and has since been one of
the most widely studied G-quadruplex binders (Figure 1). BRACO19 has been reported to
inhibit telomerase which causes telomere shortening

59

; its experimental in vivo activity

against a variety of cell lines is reported (Table 1). Furthermore, BRACO19 have been
shown effective in anti-viral, and anti-parasitic treatments. BRACO19 also demonstrates
broad anti-viral activity by stabilizing the G-quadruplexes found in pro-viral genomes

60

such as the viruses HIV-1, HSV-1, EBV, HHV-6, and HBV 61. BRACO19 also showed in
vitro anti-parasitic activity in bloodstream forms of T. brucei brucei, against promastigotes
of L. major, against P. falciparum 62, as well as against a human non-tumoral lung cell
line (MRC-5)

63

. A major factor that has prevented BRACO19 from clinical usage is a low
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selectivity towards G-quadruplex over duplex DNA (K_quad/K_dup=40 fold, K: ligand
binding constant)

58

, which has the potential to cause reverse effects. To achieve higher

selectivity (e.g. 105 fold), better understanding of the binding nature of BRACO19 with
DNA G-quadruplex and duplex DNA is required.

Figure 1. Chemical Structure of BRACO19.
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Table 1
In vivo activity of BRACO19 against various cancer cell lines.
Cell lines
Tissue type
IC50
MCF7
Breast cancer (human)
2.5μM
A549
Lung cancer (human)
2.4μM
DU145
Prostate cancer (human)
2.3μM
HT-29
Colon cancer (human)
2.7μM
HGC-27
Gastric carcinoma
2.6μM
A2780
Ovarian cancer (human)
2.5μM
WI-38
Lung fibroblast (human)
10.7μM
IMR90
Lung fibroblast (human)
>25μM
U87
Glioblastoma (human)
1.45μM
U251
Glioblastoma (human)
1.55μM
SHG-44
Glioma (human)
2.5μM
UXF1138L
Uterus carcinoma (human)
2.5μM
CH1
Lymphoma (mouse)
10.1μM
SKOV3
Ovarian cancer (human)
13.0μM
CLL
Chronic lymphocytic leukemia
80μM
AML
Acute myeloid leukemia
80μM
-Prolymphocytic leukemia
80μM

References
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64, 72
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Despite the high interest of BRACO19 in complex with biologically relevant single
stranded

intramolecular

DNA

G-quadruplex

formed

by

one

chain

(e.g.,

d(AGGGTTAGGGTTAGGGTTAGGG) ), there are no high-resolution structures of
BRACO19 binding to the antiparallel or the hybrid topology. The only high-resolution
structure available is a bimolecular parallel G-quadruplex in complex with BRACO19
(PDB ID: 3CE5), where the intermolecular G-quadruplex is formed from two 12-residue
chains (i.e., d(TAGGGTTAGGGT) ). 80 Because bimolecular (12mer) or intramolecular
(22mer) adopt the same parallel topology, suggested by Parkinson et al.
confirmed by Phan et al.

81

35

and later

in both Na+ or K+ in solution under crowded conditions, this

crystal structure provides the following invaluable interaction insights:

BRACO19

interacts asymmetrically with the guanine bases of the intermolecular G-quadruplex
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through π–π interactions and the nitrogen atom of the acridine ring aligns with the K+
cations within the ion pore. Nonetheless the additional 5’ and 3’ residues at the two ends
could introduce artifacts when comparing the BRACO19 binding modes on the
biologically relevant unimolecular parallel scaffold formed the single stranded telomeric
sequence. To remove the artifacts, we used another crystal structure (PDB ID: 1KF1)
containing the apo form of the parallel intramolecular telomeric G-quadruplex in our
BRACO19 binding studies. Furthermore, because the most biologically relevant form may
not be the parallel form, the binding of BRACO19 to the antiparallel and the hybrid form
are required to better understand its biology relevant binding mode leading to its anticancer properties. 28, 50
2.1.4 Experimental overview. In this work, by using free ligand MD binding
simulations with AMBER OL15 DNA and GAFF2 ligand force fields

82

(Table 2), we

were able to predict a binding mode of BRACO19 to the double stranded parallel telomeric
G-quadruplex that is consistent with the crystal complex structure (PDB ID: 3CE5).
Furthermore, the binding modes and the ligand binding pathways were characterized in
detail. We extended our free ligand MD simulations to characterize the binding pathway
of BRACO19 to the parallel, anti-parallel, hybrid DNA G-quadruplexes and duplex DNA
(Figure 2). Major binding poses, (top binding, bottom binding and groove binding) were
identified and detailed binding pathways were characterized. The dynamic and energetic
properties of the three major binding modes were thoroughly studied. We suggest that the
similar binding energy of the groove binding pose to the duplex and of the top stacking
pose to the parallel G-quadruplexes may be responsible for the low selectivity (40 fold) of
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BRACO19. This study may provide insight into the further modification of BRACO19 and
other G-quadruplex binders to enhance overall selectivity and efficacy.

Table 2
Molecular dynamics simulations systems
ID

DNA

No. of
ligand

No.
run

1
2
3
4
5
6
7
8
9

n/a
Duplex(d([GC]10)2)
3(-p-p-p) (1KF1)
3(-lwd+ln) (143D)
3(-p-lw-ln) (2HY9)
Duplex(d([GC]10)2)
3(-p-p-p) (1KF1)
3(-lwd+ln) (143D)
3(-p-lw-ln) (2HY9)

1
0
0
0
0
1
1
1
1

2
2
2
2
2
9+1
8+2
9+1
9+1
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Drug
Initial
State
Free
Free
Free
Free
Free
Free
Free
Free
Free

NPT
eq.
(ns)
1
1
1
1
1
1
1
1
1

NVT (ns)
500
500
500
500
500
500+2000
500+2000
500+2000
500+2000

Total
time
(µs)
1
1
1
1
1
6.5
8.0
6.5
6.5

A

B

C

D

Figure 2. Structure of human telomeric duplex DNA (A), human telomeric parallel DNA
G-quadruplex (PDB ID: 1KF1) 3(-p-p-p) (B), human telomeric anti-parallel DNA Gquadruplex (PDB ID: 143D) 3(-lwd+ln) (C), and human telomeric hybrid DNA
quadruplex (PDB ID: 2HY9) 3(-p-lw-ln) (D). 5’ and 3’ ends of the DNA chain are
indicated by red and blue spheres, respectively.
23

2.2 Methods
2.2.1 Molecular dynamic simulation system setup. A total of 9 systems were
constructed: a BRACO19 only system, a B-DNA duplex structure of d([GC]10)2, the Xray crystal structure of the parallel telomeric DNA G-quadruplex, the NMR solved antiparallel telomeric DNA G-quadruplex and the NMR-solved hybrid telomeric DNA Gquadruplex and four DNA-ligand systems (Table 2). The B-DNA duplex structure of
d([GC]10)2 was built using Maestro program. The four free ligand-DNA systems were
constructed with a free BRACO19 molecule that was 10 Å away from the DNA (Figure
A1). A water box of truncated octahedron with 10 Å water buffer was used to solvate the
unbound system and was neutralized by K+ and 0.15 M KCl was added. The DNA
structures were represented by a refined version of the AMBER DNA OL15 (i.e.,
parm99bsc0 83 +χOL4 84+ ε/ζOL1 85 + βOL1 86 updates), water was represented by TIP3P
model 87 and the K+ ions were represented by the K+ model developed by Cheatham
group 88. The standard AMBER protocol was used to obtain the force field for the
BRACO19 molecule: after the geometry optimization of BRACO19 at the HF/6-31G*
level, the molecular electrostatic potential (MEP) of the BRACO19 molecule was
calculated at the same theory level; then the partial charges of BRACO19 atoms were
determined by MEP using Restrained Electrostatic Potential/RESP method with two
stage fitting 89; and the AMBER GAFF2 90 force field provided the rest of the force field
parameters. The supporting document of our previous paper 82 provides the BRACO19
force field in Mol2 format. The nucleic acid simulations have been widely practiced in
AMBER DNA force fields 91-95. In our previous studies, the binding pathways of
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doxorubicin 96 and Telomestatin 97, anti-cancer drugs to the B-DNA fragment 96 and to
the human telomeric hybrid G-quadruplex 97, respectively, have been simulated.
2.2.2 Molecular dynamics simulation protocols. The ten production runs for all
complex systems were conducted using the AMBER 16 simulation package
detailed protocol followed our previous studies

96 97

90

. The

. After minimizing the energy, the

Maxwell-Boltzmann distribution was used to conduct all simulation runs with different
initial velocities, which were assigned based on random seeds. For the free binding system,
an extra 500 ps pre-run at high temperature (500 K) was carried out to randomize the
position and orientation of the free ligand, while the receptor was fixed. Better sampling of
binding poses and pathway was enabled by multiple independent simulations. To
equilibrate the system density, a short 1.0 ns MD simulation in the NPT ensemble mode
(constant pressure and temperature) was conducted, where the DNA and ligand were
subjected to Cartesian restraints (1.0 kcal/mol/Å). For the 500 ns production run, the NVT
ensemble mode (constant volume and temperature) was used to enhance the simulation
code stability. The representative trajectory for major binding modes was picked from each
system and extended to 2000 ns. All bonds connecting hydrogen atoms were constrained
by SHAKE 98 which enabled a 2.0 fs time step in the simulations. Long-range electrostatic
interactions under periodic boundary conditions were treated using the particle-mesh
Ewald method 99 (the fourth order of the B-spline charge interpolation, charge grid spacing
of ~1.0 Å; and direct sum tolerance of 10–5). The cutoff distance for short-range nonbonded interactions was 10 Å, with the long-range van der Waals interactions based on a
uniform density approximation. To reduce the computation cost, a two-stage RESPA
approach

100

was used to calculate non-bonded forces where the short range forces was
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updated once per time step and the long range forces was updated twice per time step. The
Langevin thermostat with a coupling constant of 2.0 ps was used to control the temperature.
The trajectories were saved at 50.0 ps intervals for analysis.
2.2.3 Checking the convergence of the simulations. The initial structure was
used as a reference to calculate the root mean square deviation (RMSD) of DNA
backbone. The stability of the DNA structures was indicated by the flat and small
RMSDs (Figures A2, A4, A6 and A8). An atom-to-atom distance cutoff of 3.0 Å was
used to calculate atom contacts between the DNA structure and BRACO19. The stable
contact number indicated the steady state of the simulation systems (Figures A3, A5, A7
and A9). We defined a stable complex as one with greater than 10 atom contacts.
2.2.4 Binding mode identification. Accounting to the stability of the DNA
backbone in the binding process, the DNA backbone of the stable complexes was aligned
by a least square fitting. Daura’s algorithm 101 was used to cluster the aligned complexes
into different structural families based on the 2 Å pair-wise RMSD cutoff of the BRACO19
only without ligand fit. The centroid structure was defined as a structure with the largest
number of neighbors in the structural family and was used to represent that structural
family. Based on visual inspection, super-families corresponding to major binding modes
were formed by merging the centroid structures (Figure 3; Figure A14-A17).
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A) DNA Duplex
B) Parallel GQuadruplex
C) Anti-parallel GQuadruplex
D) Hybrid G-Quadruplex

Figure 3. The major binding modes of BRACO19 in complex with the human telomeric
DNA. A: Duplex; B: Parallel G-quadruplex; C: Anti-parallel human telomeric Gquadruplex; D: Hybrid human telomeric G-quadruplex. A-D: Top binding (left), Bottom
binding (middle) and groove binding (right); 5’ end and 3’ end are represented by the red
and blue ball respectively.
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2.2.5 Order parameters to characterize DNA-drug binding pathway. The
DNA-drug binding process was characterized by using five order parameters: hydrogen
bond analysis, drug-base dihedral angle, DNA/ligand RMSD, center-to-center and K+-K+
distance (R) and MM-GBSA binding energy (ΔE). A hydrogen bond was defined by 3.5Å
distance cutoff between H-bond donor and H-bond acceptor and 120° donor-H-acceptor
angle cutoff. The hydrogen bonds were calculated for the top/first, middle/second and
bottom/third base tetrads. For the three G-quadruplexes, the three G-tetrads were defined
so that 5’ is close to the first G-tetrad. The dihedral angle between the plane of the stable
G-tetrad of the DNA that is close to drug binding site and the BRACO19’s ring plane was
defined as the dihedral angle. After aligning the DNA, the ligand RMSD was calculated
with reference to the first frame of the trajectory. The length from the DNA center to the
drug molecule center was defined as the center-to-center distance (R). The distance
between the K+ ions present in the DNA G-quadruplex was defined as K+-K+ distance. The
energetics of the bound complexes were analyzed using MM-GBSA54 (Molecular
Mechanics Generalized Born-Surface Area) module in the AMBER package (GB1 model
with salt concentration of 0.15M, mBondi radii set, and surface tension of 0.0072 kcal/Å2)
to avoid the large energy fluctuation of the explicit solvent.
It was reported that even when considering the relative solvation free energy, good
predictions can be made for charged molecules by the GB models on the hydration free
energy 102. Under this assumption, ions were removed from charged DNA systems in this
study. This approach was validated in our previous study, in which this MM-GBSA
protocol successfully assessed the binding energy of doxorubicin, an anti-cancer drug, to a
B-DNA fragment (d(CGATCG)2)
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. Under comparable entropic terms, the relative
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binding free energy estimated by the MM-GBSA binding energies can be used to rank
drugs or their binding poses if a single molecule is considered

104

. It has been established

by systematic benchmarking studies up to 1864 crystal complexes that ranking of the ligand
binding affinity can be achieved by relative MM-GBSA binding energy calculations
107
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. In a previous work we studied the use of MM-GBSA versus MM-PBSA as a predictor

of BRACO19’s relative binding energy (ΔΔE) over a range of ionic strengths 82. The highly
comparable relative binding energies in both the MM-GBSA and MM-PBSA calculations
supports the use of MM-GBSA in ranking the binding poses of BRACO19 in this study.
The MM-GBSA binding energy for each system was calculated from three simulations108:
ligand only, DNA only and DNA-ligand complex using equation 1. Equation 2 is made of
four components: van der Waals interaction energy (VDW), hydrophobic interaction
energy (SUR), electrostatic interaction (GBELE) and the change of the conformation
energy for DNA and ligand. These terms were calculated using equation 3 and 4.
Eq 1:

∆𝐸 = 𝐸𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝐷𝑁𝐴_𝑓𝑟𝑒𝑒 − 𝐸𝑙𝑖𝑔_𝑓𝑟𝑒𝑒

Eq 2:

∆𝐸 = ∆𝐸𝑣𝑑𝑤 + ∆𝐸𝑆𝑈𝑅 + ∆𝐸𝐺𝐵𝐸𝐿𝐸 + ∆𝐸𝑐𝑜𝑚𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛

Eq 3:

∆𝐸𝑥 = 𝐸𝑥_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑥_𝐷𝑁𝐴_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑥_𝑙𝑖𝑔_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 , x= VDW, SUR and GBELE

Eq 4: ∆𝐸𝐶𝑜𝑚𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 = 𝐸𝐷𝑁𝐴_𝑓𝑟𝑜𝑚_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 +𝐸𝑙𝑖𝑔_𝑓𝑟𝑜𝑚_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝐷𝑁𝐴_𝑓𝑟𝑒𝑒 − 𝐸𝑙𝑖𝑔_𝑓𝑟𝑒𝑒
The standard backbone dihedral angles (α, β, γ, δ, ε and ζ) around the covalent
bonds of the deoxyribose and χ about the glycosidic bond were defined (Figure A27) to
characterize the conformational changes.
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2.3 Results
2.3.1 Multiple drug binding modes were observed in free ligand binding
simulations. Starting from an unbound state, we simulated ten 500-ns production runs for
each system. The convergence of the binding simulations was confirmed (see the method
section), a sampling plot was generated to trace the position of one atom of BRACO19
through the length of the entire simulation period for each system (Figure A31). The last
snapshots from each simulated trajectory of the duplex-BRACO19 system is listed in
Figure A10 and indicate the stability of the DNA structures where the base pairing was
maintained. The last snapshots of all the simulated trajectories of the G-quadruplex-ligand
systems are listed in Figures A11, A12 and A13 and indicate the stability of the Gquadruplex structures where the G-tetrads were maintained. Multiple binding sites were
observed in the ten duplex DNA-BRACO19 trajectories. The clustering analysis described
in the methods section was employed to categorize the stable complexes that were extracted
from the trajectories into structural families. By setting a threshold of 1% population, 14
structural families of complexes were identified (Figure A14). These 8 structural families
were further merged into three binding modes: groove binding, top stacking and bottom
stacking. Binding to the groove of the duplex accounted for 81% of the total population.
Additionally, end stacking to the top of the duplex accounted for 4% and end stacking to
the bottom of the duplex made up 2% of the total population (Figure A14). Three binding
modes were observed in the ten parallel G-quadruplex DNA-BRACO19 trajectories. The
clustering analysis was employed to categorize the stable complexes that were extracted
from the trajectories into 11 structural families (Figure A15). The three binding modes
observed were: top stacking, bottom stacking and groove binding. Top stacking to the
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parallel G-quadruplex DNA accounted for 28%, bottom stacking accounted for 41% and
groove binding for 29% of the total population (Figure A15). Multiple binding sites were
observed in the ten anti-parallel DNA G-quadruplex-BRACO19 trajectories. The
clustering analysis was employed to categorize the stable complexes that were extracted
from these trajectories into 9 structural families (Figure A16). Three binding modes were
observed: top, bottom and groove binding. Bottom binding to the anti-parallel Gquadruplex DNA accounted for 46%, top binding for 25% and groove binding for 40% of
the total population (Figure A16). Multiple binding sites were observed in the ten hybrid
G-quadruplex DNA-BRACO19 trajectories. The same clustering analysis was employed
to categorize the stable complexes that were extracted from these trajectories into 11
structural families (Figure A17). Three binding modes were observed: top, groove and
bottom binding. Groove binding to the hybrid G-quadruplex DNA accounted for 43%, top
binding for 33%, and bottom binding for 20% of the total population (Figure A17). Two
dimensional interaction diagrams of BRACO19 in complex with each DNA system, in
each major binding pose, is available in the supporting document (Figure A18).
2.3.2 MM-GBSA binding energy calculations. MM-GBSA binding energy
calculations were carried out, as depicted in methods section, to examine the relative
binding affinities of the major binding modes of BRACO19 with respect to the DNA
(Table 3). From this it was clear the VDW interaction contributes most to the total
binding energy and in ranking the binding poses for each DNA-ligand system. The most
favorable binding energy for the duplex-BRACO19 complex was the groove binding
mode (-61.7±8.0 kcal/mol), followed by the bottom stacking mode (-34.6±5.7 kcal/mol)
and the top stacking mode (-33.7±5.3 kcal/mol). VDW packing, responsible for the VDW
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energy contribution, was the primary contributor to the binding energy of the three
modes. BRACO19 bound to parallel G-quadruplex DNA in three binding pose where top
stacking (-62.3±4.5kcal/mol) was the most energetically favorable, closely followed by
the bottom binding mode (-61.8±1.5 kcal/mol), and groove binding (-37.6±7.2 kcal/mol)
was the least stable of the three. BRACO19 bound to the anti-parallel G-quadruplex DNA
in three binding poses where bottom binding (-53.9±5.8 kcal/mol) was the most stable of
the three, groove binding exhibiting a binding energy of -43.1±7.2 kcal/mol and top
binding had the lowest binding energy (-42.8±4.1kcal/mol). BRACO19 bound to the
hybrid G-quadruplex DNA in three binding poses as well. Top binding (-40.5±5.4
kcal/mol) was the most stable of the three, followed by groove binding (-35.7±5.1
kcal/mol) and bottom binding (-29.0±12.9 kcal/mol).
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Table 3

MM-GBSA binding Energy (kcal/mol) of BRACO19 to human telomeric DNA duplex
and Quadruplexes.
System

DNA
Duplex

Paralle
l Quad

AntiParalle
l Quad

Pose
Top
Botto
m
Groov
e
Top
Botto
m
Groov
e
Top
Botto
m
Groov
e
Top

Hybrid
Quad

Botto
m
Groov
e

1ΔE

VDW

2ΔE

SUR

3ΔE

GBELE

4ΔE

CONF

5ΔE
TOT

6ΔΔ

-28.9±4.0

-2.3±0.5

-5.2±3.1

2.7±1.2

-33.7±5.3

ETOT
28.6

-28.4±4.1

-2.2±0.5

-4.8±3.2

0.8±3.8

-34.6±5.7

27.7

-57.9±9.5

-5.2±0.7

-3.9±4.5

5.2±2.8

-61.7±8.0

0.6

-5.2±0.6
3.79±0.2
-3.1±0.4

-1.9±4.4
11.35±2.0
-8.9±4.5

7.9±5.2
-2.2±3.9

-62.3±4.5
-61.8±1.5

0
0.5

11.4±4.5

-37.6±7.2

24.7

-2.5±0.8

-9.2±3.0

-2.1±4.4

-42.8±4.1

19.5

-4.0±1.1

-8.5±4.3

0.1±4.6

-53.9±5.8

8.4

-3.4±0.5

-7.5±2.6

10.9±2.3

-43.1±7.2

19.2

44.2±11.4

-4.3±1.0

-12.1±5.0

20.0±9.2

-40.5±5.4

21.8

-25.7±5.8

-2.8±0.7

-16.3±6.0

15.8±8.5

29.0±12.9

33.3

-40.5±6.6

-4.0±0.5

-14.9±5.2

23.7±3.6

-35.7±5.1

26.6

-63.1±5.7
-44.5±3.3
-37.0±6.4
-29.1±9.0
41.5±11.4
-43.0±6.0

2.3.3 Binding of BRACO19 to the duplex DNA. BRACO19 binds to the groove
of the duplex DNA, without inducing appreciable DNA structure fluctuation. The
representative trajectories for the three major binding modes of BRACO19 to the human
telomeric duplex DNA (Figure 4 and Figure A19). In all ten binding trajectories, the DNA
showed low structural fluctuation with a RMSD of 2.4 Å (Figure A2) where the hydrogen
bonds between the base pairs were maintained. In the representative trajectory of
BRACO19 binding to the groove of the human telomeric duplex DNA in Figure 4, an initial
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interaction was observed as early as 3 ns and the final binding pose was achieved at ~14 ns
which was maintained throughout the remainder of the trajectory. The limited fluctuation
in the five order parameters explained the limited structural dynamics. The other
representative trajectory of BRACO19 groove binding (Figure A19) also exhibited rapid
binding and limited dynamics.
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02 ns

11 ns

275 ns

837 ns

1333 ns

2000 ns

Figure 4. A representative groove binding trajectory of the duplex DNA. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. Bottom: receptor (red) and ligand (black) RMSD relative to the original
crystal pose, center-to-center distance and MM-GBSA binding energy (ΔE) (cf. methods
section for definition).
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2.3.4 Binding of BRACO19 to the parallel G-quadruplex. The representative
trajectories for the two major binding modes of BRACO19 to the parallel human telomeric
G-quadruplex DNA (Figure 5 and A20) (the top stacking mode) and Figure A21 (the
bottom stacking mode). In all ten binding trajectories, the DNA showed low structural
fluctuation with RMSD of 2.4 Å (Figure A4) and the hydrogen bonds in the three G-tetrads
were maintained. In the representative trajectory of BRACO19 binding to the top of the
human telomeric parallel G-quadruplex DNA in Figure 5, an initial interaction was
observed as early as 2 ns. BRACO19 underwent several top pose adjustments until ~750
ns when the final binding pose was achieved and maintained throughout the remainder of
the trajectory. Despite the repositions of BRACO19 in the early portion of the simulation,
there were limited fluctuations in the order parameters. The other representative trajectory
of the top stacking mode of BRACO19 binding to parallel G-quadruplex (Figure A20) also
exhibited quick binding and limited dynamics, with the early interaction to the complex at
4 ns and attaining the stable top binding pose at 25 ns where it maintained the top staking
pose with minor repositions until 1391 ns where it remained for the length of the trajectory.
The representative trajectory for the bottom binding pose (Figure A21) achieved the final
binding pose within 10 ns and displayed high stability as indicated by the limited
fluctuations in the order parameter plot. The binding energy for top/bottom stacking
fluctuated between -60 and -75 kcal/mol while groove stacking varied between -35 and 45 kcal/mol after attaining a stable binding pose.
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Figure 5. A representative top stacking trajectory of the parallel G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. K+ ions are represented in yellow. Bottom: An order parameter plot
depicting number of hydrogen bonds present in first G4 (green), second G4 (red) and
third G4 (blue) tetrads of the DNA structure (Figure 2), the drug-base dihedral angle,
receptor (red) and ligand (black) RMSD relative to the original crystal pose, center-tocenter distance (R/black) and K+-K+ distance (R/red) and MM-GBSA binding energy
(ΔE) (cf. methods section for definition).
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Major fluctuations were observed in the terminal residues, however T6 in
particular is discussed here as it demonstrates highest fluctuation. T6 flipped out at 15 ns
and flipped back at 45 ns, flipped out at 69 ns and flipped in at 100 ns and it finally
flipped out at 114 ns and remained same throughout the rest of the trajectory. This
flipping out of the base is mainly characterized by α, β, γ and χ (Figure 6). Another
example of BRACO19 binding to the parallel scaffold facilitated by base flipping is
illustrated in Figure A30A which shows the terminal residue A1 clearly flipping outward
which provided adequate space for BRACO19 to bind to the top G-quartet, closest to the
5’ end.

Figure 6. Histograms comparing the backbone torsion angles of residue T6 between the
free ligand binding simulation (red) of the top stacking mode of the parallel G-quadruplex
and the stability simulation of the crystal structure (blue) of the parallel G-quadruplex
within last 200 ns.
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2.3.5 Binding of BRACO19 to the anti-parallel G-quadruplex. The
representative trajectories for the three major binding modes of BRACO19 to the antiparallel human telomeric G-quadruplex DNA are characterized in Figure 7 and A23 (the
bottom stacking mode) and Figure A22 (the top binding mode). In all ten binding
trajectories, the DNA showed high structural fluctuation in four trajectories with RMSD of
3.2 Å (Figure A6), the hydrogen bonds in the three G-tetrads were maintained and the
distance between K+ ions remained stable in all trajectories. The representative trajectory
of the bottom stacking mode of BRACO19 (Figure 7) on the human telomeric anti-parallel
DNA G-quadruplex showed an initial interaction at 5 ns. The final binding pose was
achieved within 48 ns and was maintained throughout the rest of the trajectory. The limited
structural dynamics were explained by the limited fluctuation in the five order parameters.
The representative trajectory for the top binding mode (Figure A22) is similar to the bottom
binding trajectories with a rapid binding and limited fluctuation of order parameters with
first interaction at 5 ns and attainment of the final binding pose by 55 ns. The binding
energy for bottom stacking and groove binding fluctuated between -55 and -65 kcal/mol
while top stacking varied between -40 and -50 kcal/mol after attaining a steady binding
pose.
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Figure 7. A representative bottom stacking trajectory of the anti-parallel G-quadruplex.
Top: Representative structures with time annotation. 5’ and 3’ are indicated by a red and
blue ball, respectively. K+ ions are represented in yellow. Bottom: An order parameter plot
depicting number of hydrogen bonds present in first (red), second G4 (cyan), third G4
(blue), fourth G4 (black) and fifth (green) layers of the DNA structure , the drug-base
dihedral angle, receptor (red) and ligand (black) RMSD relative to the original crystal pose,
center-to-center distance (R/black) and K+-K+ distance (R/red) and MM-GBSA binding
energy (ΔE) (cf. methods section for definition).
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The dihedral angles of the G-tetrads in free ligand binding simulations indicate
low fluctuations and are consistent through the binding process. Major fluctuations were
observed in the terminal residues, T5 in particular is discussed here as it demonstrates
highest fluctuation. Through the binding process BRACO19s major interaction was with
T5, which opened up as BRACO19 approached and at 29 ns flipped out to let BRACO19
in and flipped back at 40 ns and staying open after interacting with BRACO19. This
flipping out of the base is mainly characterized by ε and ζ (Figure 8). Another example
of this base flipping for the anti-parallel topology is illustrated in Figure A30B, where
BRACO19’s major interaction is with base A7. As a result of BRACO19’s interaction
with base A7, the base T5 flips upward allowing base A7 to flip to the outside of
BRACO19 maximizing the binding interactions between the G-quadruplex and
BRACO19. The base T5 remains flipped up for the remainder of the trajectory and the
interaction where A7 is partially intercalating BRACO19 onto the G-quadruplex is also
maintained.
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Figure 8. Histograms comparing the backbone torsion angles of residue T05 between the
free ligand binding simulation (red) of the top stacking trajectory of the anti-parallel Gquadruplex and the stability simulation of the crystal structure (blue) of the anti-parallel Gquadruplex.

2.3.6 Binding of BRACO19 to the hybrid G-quadruplex. The representative
trajectories for the three-major binding modes of BRACO19 with respect to the hybrid
human telomeric G-quadruplex DNA are characterized in Figure 9 and A24 (the top
binding mode), Figure A25 (the bottom binding mode) and Figure A26 (the groove binding
mode). Out of the ten binding trajectories, the DNA showed high structural fluctuation in
five trajectories with RMSD of 2.9 Å (Figure A8), the hydrogen bonds in the three Gtetrads were maintained and the distance between K+ ions remained stable in all
trajectories. The representative trajectory of BRACO19 top stacking onto the hybrid Gquadruplex DNA showed an initial interaction at 3 ns, the final binding pose was attained
as early as 30 ns and was maintained throughout the rest of the trajectory. The limited
structural dynamics were explained by the limited fluctuation in the five order parameters.
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The representative trajectories of the bottom (Figure A25) and groove binding (Figure
A26) are similar to the top binding trajectories in rapid binding and limited fluctuation of
order parameters. Early interaction of BRACO19 with the quadruplex was at 9 ns and 2 ns
respectively and the final binding pose was attained by 51 and 13 ns respectively. The
binding energy for all binding modes varied between -55 and -65 kcal/mol after attaining
the steady binding pose.
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Figure 9. A representative top binding trajectory of the hybrid G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. K+ ions are represented in yellow. Bottom: An order parameter plot
depicting number of hydrogen bonds present in first (red), third G4 (blue), and fifth (green)
layers of the DNA structure, the drug-base dihedral angle, receptor (red) and ligand (black)
RMSD relative to the original crystal pose, center-to-center distance (R/black) and K+-K+
distance (R/red) and MM-GBSA binding energy (ΔE) (cf. methods section for definition).

The dihedral angles of the G-tetrads in free ligand binding simulations indicate
low fluctuations and are consistent through the binding process. Major fluctuations were
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observed in the terminal residues, T8 in particular is discussed here as it demonstrates
highest fluctuation. T8 flipped out upon simulation and remained flipped through a
majority of the simulation. This flipping out of the base is mainly characterized by α, δ, ε
and ζ (Figure 10). Another example for the hybrid scaffold is presented in Figure A30C.
The initial binding of BRACO19 was to the groove of the G-quadruplex before
interacting with the 3’ terminal residue which appeared to steer BRACO19 toward a
bottom binding interaction. In this trajectory, both the 3’ terminal residue A23 as well as
loop residue T13 flip upward (clear in the 48 ns snapshot) which allowed BRACO19 to
bind to the bottom of the G-quadruplex. Bases A23 and T13 made slight adjustments in
their position for the remainder of the trajectory, whereas BRACO19 remained stably
bound to the bottom of the G-quadruplex.

Figure 10. Histograms comparing the backbone torsion angles of residue T8 between the
free ligand binding simulation (red) of the top binding trajectory of the hybrid Gquadruplex and the stability simulation of the crystal structure (blue) of the hybrid Gquadruplex within the last 200 ns.
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2.4 Discussion
After the discovery of the greater existence of G-quadruplexes in malignant tumors
than in normal tissues, the interest in G-quadruplex DNA as a target for cancer therapeutics
has increased. BRACO19, an effective G-quadruplex stabilizing ligand, is a promising
anticancer drug candidate, yet its low preferential binding affinity (about ~40-fold) to the
telomeric single-stranded G-quadruplex DNA over duplex DNA remains to be enhanced.
For better molecular insights, the binding of BRACO19 to a duplex 20mer DNA
(d([GC]10)2) and to the parallel, anti-parallel and hybrid telomeric G-quadruplexes were
investigated in this study using free ligand binding molecular dynamics simulations. Out
of various binding modes for each system, the MM-GBSA binding energy calculations
showed that the most stable binding pose was the groove binding mode for the duplex, the
top/bottom stacking mode for the parallel G-quadruplex, the bottom stacking mode of the
anti-parallel G-quadruplex and the top stacking mode of the hybrid G-quadruplex (Table
3). The order of the relative binding energy of BRACO19 to these DNA forms are as
follows: -62.3±4.5 kcal/mol of the top stacking to the parallel G-quadruplex (ΔΔE=0
kcal/mol), -61.7±8.0 kcal/mol of the groove binding to the duplex DNA (ΔΔE=0.6
kcal/mol), -53.9.4±5.8 kcal/mol of the bottom stacking to the anti-parallel G-quadruplex
(ΔΔE=8.4 kcal/mol) and

-40.5±5.4 kcal/mol of the top stacking to the hybrid G-

quadruplex (ΔΔE=21.8 kcal/mol). For all the systems, breaking down the binding energy
indicated that the VDW term makes the biggest contribution to the total binding energy
(Table 3). This indication suggests introducing target or drug specific packing optimization
as a prospect for further stabilization of the G-quadruplex. A limitation of the MMPBSA
binding energy calculations are that they do not include the conformational changes
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involved in the folding process of the G-quadruplexes nor do they consider the relative
stability of the different scaffolds. Because of this, MMPBSA calculations alone may not
be sufficient enough to predict the most favorable scaffold under physiological conditions.
There are the two lines of conflicting evidences on major target form of BRACO19:
1). under the solution condition with cellular extracts as crowding agents, the more
predominate conformations are likely the anti-parallel and/or the hybrid topologies. 2).
There is no high-resolution complex structures of BRACO19 binding to antiparallel or the
hybrid scaffold, except for parallel stranded. Our binding energy data suggest a hypothesis
that reconcile the conflict: the relative population shift of three scaffolds upon BRACO19
binding (i.e., an increase of population of parallel scaffold, a decrease of populations of
antiparallel and/or hybrid scaffold). This hypothesis appears to be consistent with the facts
that BRACO19 was specifically designed based on the structural requirements of the
parallel scaffold and has since proven effective against a variety of cancer cell lines as well
as toward a number of scaffolds.
With groove binding predicted to be the least energetically favorable, and based
on our visual inspection of each trajectory, our data suggests that BRACO19’s groove
binding pose is likely not stable enough to maintain a prolonged binding event and that
under a more extended timeline the groove binding mode may function as an intermediate
state preceding a more energetically favorable end stacking pose. To support this, Figure
A29 A-C provides representative snapshots of three simulation runs from each Gquadruplex system are presented. As for the anti-parallel system, we attribute the
comparable top and groove binding poses to the anti-parallel topology. Based on our
observations the diagonal loop (T11, T12, A13) atop the G-quartet, closest to the 5’
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terminal, obstructs BRACO19’s ability to achieve a stable stacking pose on the top Gquartet. Therefore BRACO19’s major interaction with the top of the anti-parallel Gquadruplex is with the TTA diagonal loop, which offers no benefit over the groove binding
pose in terms of binding interaction.
If these binding modes have comparable entropic energies then our relative binding
energies suggest that BRACO19 binds preferentially to the parallel G-quadruplex over the
anti-parallel and the hybrid G-quadruplexes if assuming equally abundant conformations
in physiological condition. In the same way, our relative binding energy data shows that
BRACO19 binds preferentially to the telomeric parallel G-quadruplexes over the DNA
duplex. This qualitatively explains the experimental observation of weak preferential
binding affinity difference of BRACO19 on the two DNA forms (40 fold of the selectivity).
For that reason, it can be suggested that a ligand modification that destabilizes the duplex
groove binding mode but stabilizes the G-quadruplex top stacking mode will enhance the
binding selectivity of the ligand. For example, adding a rigid planar ring fragment to the
acridine may facilitate top stacking rather than groove binding and increase the van der
Waals interactions in turn increasing selectivity and binding affinity of the prospective drug
towards the G-quadruplex. This suggestion is consistent with the original SAR data in the
development of BRACO19 from prototype BSU6048 in which the addition of the ring at
position 9 (makings of BRACO19) increased the drug selectivity from 10-fold to 40 fold
towards human telomeric G-quadruplexes over duplex DNA 57, 109, 110. The addition of the
methylated anilino group, as opposed to the hydrogenated aniline at the 9th position slightly
decreased binding to the duplex, while maintaining binding to the G-quadruplex

111

. It is

also to be noted that the sidechains on 3 and 6 contribute to the groove binding of both
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DNA duplex and G-quadruplex which could be the reason behind low selectivity. We
observed the side chains of the 3rd and 6th position to play a role in BRACO19’s ability to
fully bind to the groove of the duplex DNA, but the side chains appear to play less of a role
in G-quadruplex binding; which we primarily observed as an interaction with the acridine
core. Thus, suggestions can be made to reduce the length of these side chains. These side
chains exist in protonated form at physiological pH however, Table 3 indicates that the
contribution of electrostatic interactions to the binding affinity is very low and therefore
modifications can be suggested to the substituents at 3rd and 6th position of the acridine.
Modifications such as loss of positive charge which would increase the hydrophobicity
which could in fact increase the van der Waals interactions and reduction of the length of
the side chains.
Encouragingly, the binding pose of BRACO19 to the parallel human telomeric Gquadruplex is consistent with to the only available crystal structure of BRACO19 (PDB
ID: 3CE5) (Figure 11). In both the crystal structure and the structure from our study, the
acridine core binds to the G-quartet closest to the 3’ terminal with the nitrogen from the
acridine core facing inward in-line with the K+ cations. The anilino group at the 9th
position faces away from the G4 core and the two substituents at the 3rd and 6th position
are also positioned outward, allowing the drug to remain planar and stack onto the Gquartet. Although a top binding pose was not reported in the crystal structure of the
double stranded parallel topology, our study suggests due to the symmetry of the single
stranded parallel G-quadruplex topology both the top and bottom of the G-quadruplex
core offer comparable binding opportunities for BRACO19. In support of this, our MMGBSA analysis (Table 3) showed the most energetically favorable top and bottom
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binding modes were within 0.5 kcal/mol; where the top binding pose (-62.3±4.5
kcal/mol) was slightly more favorable than the bottom binding pose (-61.8±1.5 kal/mol).
Our study also clearly showed BRACO19 in a top binding pose closely matching the
description published for the bottom stacking in the crystal structure (Figure 11).
Together this provides evidence to support that both end stacking modes could offer
equal binding for BRACO19 in the single stranded parallel scaffold of the human
telomeric DNA G-quadruplex. In addition to this, a crystal structure of a Pt-tripod in
complex with the hybrid DNA G-quadruplex sequence was recently solved (PDB ID:
5Z80), which shows binding to the top of the G4 similar to the binding pose observed in
our study (Figure A28).

Figure 11. Comparison of the Double Stranded parallel G-quadruplex-BRACO19
complex (PDB ID: 3CE5) and both the Bottom and Top Binding Modes of the Single
Stranded parallel G-quadruplex-BRACO19 complex. The 5’ residues are represented by a
red ball and the 3’ residues in blue.
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Although longer simulation periods are required to confirm, evidence of an induced
fit binding mechanism was observed in each of the BRACO19-G-quadruplex complexes.
The representative trajectories in Figures 5, 7 and 9 show one example per system where a
base flipping mechanism worked to enhance the binding of BRACO19 to the receptor. The
base flipping mechanism was ongoing and recurrent through conformational changes that
occurred during the binding event. Despite an absolute equilibrium not being reached under
the restricted simulation period, the persistent use of the base flipping mechanism and the
resultant beneficial binding interactions, as observed over the timeline of the MMGBSA
energy analysis, suggest the potential use of an induced fit binding mechanism facilitated
by base flipping. We also provide a detailed analysis of the dihedral angles of the residue
showing the largest fluctuation in each system compared to the apo form. The dihedral
angles helped to characterize the changes of the bases that may contribute to an induced fit
binding mechanism. Including a description of the binding events of a second example
from each system illustrated in Figure A30. This figure demonstrates three important
characteristics that suggest the use an induced fit binding mechanism used by BRACO19.
For the parallel topology (Figure A30A), the flipping out of the 5’ terminal base A1 led to
the repositioning of BRACO19 on top of the top G-quartet. We observed two possible
outcomes for the mechanism involving 5’ terminal base flipping: (i) the 5’ base will flip
back on top of BRACO19 intercalating it onto the top G-quartet or (ii) the 5’ terminal base
will position itself in plane with BRACO19 and base pair; both mechanisms enhance the
binding interactions between BRACO19 and the DNA G-quadruplex. The anti-parallel
DNA G-quadruplex (Figure A30B) provides an example of two bases from the same loop
changing position in order to enhance the binding of BRACO19 to the DNA G-quadruplex.
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In this case, the flipping upward of base T5 during the simulation run allowed base A7 to
flip outward and reposition itself around the outside of BRACO19 so that BRACO19 was
partially intercalated to the groove of the DNA G-quadruplex which maximized its binding
interactions. The hybrid topology (Figure A30C) provides an example of both a terminal
and loop residues flipping outward to allow BRACO19 to reposition into a binding pose
that enhances its binding interactions. In this case, the 3’ terminal residue A23 and loop
residue T13 both flip outward allowing BRACO19 to stack to the bottom of the Gquadruplex. Residue A23 flips back on top of BRACO19 intercalating it while T13 remains
flipped outward to provide sufficient room for BRACO19. Together with the analysis of
the dihedral angles, the flexibility of both the terminal and loop residues -which through
their conformational changes allow BRACO19 to positon itself in a more favorable binding
pose and enhance its binding interactions- show characteristics of an induced fit binding
mechanism. It was by use of the free ligand MD binding simulations, as opposed to rigid
body docking, that we were able to observe the flipping of the terminal and loop bases
during the binding process which we suggest are integral for BRACO19 to achieve the
most favorable binding pose.
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Chapter 3
To Probe the Binding of CX-5461, an Anti-Cancer DNA G-Quadruplex Stabilizer,
to Human Telomeric, c-KIT-1, and c-Myc G-Quadruplexes and a DNA Duplex
Using Molecular Dynamics Binding Simulations
3.1 Introduction
3.1.1 DNA G-quadruplexes as anti-cancer targets. The use of DNA GQuadruplexes (G4s) as novel therapeutic targets has been a rapidly developing field over
the last decade because compounds targeting the G4s have demonstrated a high potential
against a variety of cancer cell lines. DNA G-quadruplexes demonstrate very useful
characteristics as drug targets including high diversity, stability and much slower
dissociation when compared to DNA duplexes.

112, 113

With well over 300,000 sequence

motifs identified within the human genome, the design of small molecules targeting G4s
as anti-cancer agents has become a primary focus of many researchers. 114-116
3.1.2 CX-5461 as an anti-cancer agent. Small molecule CX-5461 (Figure 12) is
a DNA G-quadruplex stabilizer whose structure contains a rigid benzothiazole-based core
and two flexible side chains: methyl diazepane based (R1) and methylpyrazine based (R2).
CX-5461 was designed for superior in vivo stability and pharmacokinetics currently in
Phase I/II clinical trials for advanced hematologic malignancies and cancers with BRCA1/2
deficiencies117. CX-5461’s first working mechanism was identified as G4 binder directly
inhibiting the binding of RNA Polymerase I, which has implications for cancer
therapeutics.118 More specifically, by binding to ribosomal DNA (rDNA) G4s formed
within the rDNA promoter, CX-5461 prevents the binding of the transcription factor, SL1,
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and subsequently RNA Polymerase I, to the rDNA promoter which prevents the
transcription of rDNA.119, 120 Recently a second, unexpected, mechanism was identified for
CX-5461 whereby it disrupts the cells replication fork by binding to and stabilizing
chromosomal DNA G4 structures in cancer cells. Although experiments have yet to
identify specific G4 targets for CX-5461 in the human genome, experimental evidence
discovered CX-5461’s specific roles at DNA G4s include the ability to selectively bind to
and stabilize G4 structures of human cells lines in vitro, and increase the number of in vivo
G4 structures. 117 These properties are extremely advantageous for cancer therapeutics, and
evident from recent work, CX-5461 is a promising therapeutic agent for a variety of targets.
In fact, as research expands, so do the number of potential targets for CX-5461 including
solid tumors121, acute myeloid leukemia122, 123, multiple myeloma124, 125, neuroblastoma
tumors126, prostate cancer127, osteosarcoma128, acute lymphoblastic leukemia129,

130

,

epithelial ovarian cancer131-133, arterial injury-induced neointimal hyperplasia134, and even
non-cancerous diseases such as cytomegalovirus135, 136, Herpes Simplex type I virus135, and
African trypanosomiasis137. However, without an experimentally solved structure of CX5461 in complex with any G4 structure the specific interactions associated with the binding
of CX-5461 and ultimate stabilization of the G4 remains to be fully understood.
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Figure 12. Chemical Structure of CX-5461. Two distinct regions are defined here where
the region outlined in black represents the rigid core of CX-5461 and the two side chains
(R1 and R2) represent flexible regions of CX-5461.

3.1.3 Experimental motivation. It is critical for G4 stabilizers to have a high
binding affinity to G4’s and demonstrate high selectivity over DNA duplexes to reduce the
reverse effects. Experimentally, this has been shown using a DNA duplex as a negative
control compared to several G4 targeting ligands which have effectively demonstrated a
higher affinity and selectivity towards G4s over DNA duplexes.112, 138 In one study, Xu et.
al performed a FRET-melting temperature increase assay to test CX-5461’s stabilizing
effects to the canonical DNA duplex structure and three different G4 forming sequences
which have been implicated in the cancerous complications resulting from BRCA1/2
mutations (human telomeric, c-KIT1, and c-Myc) 139-144. Using the double stranded DNA
duplex as a negative control to the G4 systems117, the melting temperatures of each system
was measured in the apo form. Then CX-5461 was added to each system to measure the
increase in melting temperature upon CX-5461 binding to each DNA fragment, where a
higher increase in melting temperature indicates a higher stabilizing effects thus higher
binding affinity. The results of the FRET melting temperature assay indicated that with 10
55

µM CX-5461 the highest melting temperature increase was demonstrated by the human
telomeric system (~30 K) followed by the c-KIT1 (~27 K) and c-Myc (~25 K) G4s and the
DNA duplex (~10 K). Thus, these results show that the stabilizing effect due to CX-5461
binding was highest in the human telomeric complex followed by the c-KIT1 and c-Myc
G4s and then the DNA duplex. The difference in melting temperature increase between the
G4s and duplex complex systems (15+ K) suggest that CX-5461 can selectively bind to
and stabilize G4 structures over duplex DNA117. Along with the three G4 systems having
significantly higher melting temperatures than the DNA duplex, they also varied from each
other. Due to this, it is essential to compare the binding modes and mechanisms of CX5461 in complex with the G4s versus the DNA duplex to identify specific differences that
may help explain the higher binding affinity and selectivity demonstrated by CX-5641 to
the G4s over the duplex and the variance among three G4s.
3.1.4 Experiment design overview. Based on the three G4 forming sequences
used in the FRET melting temperature assay performed by Xu and coworkers117, the
solved G4 scaffolds were obtained from the Protein Data Bank and used in this study.
These include a human telomeric G4 (PDB ID: 1KF1), c-KIT1 G4 (PDB ID: 4WO3), and
c-MYC promoter G4 (PDB ID: 2MGN)145-147 (Figure 13). Due to the sequence difference
these G4s also vary in structure. The human telomeric DNA G4 (Figure 13A;E) is made
of four parallel DNA strands with three linking TTA trinucleotide loops which connect
the top of one stand to the bottom of another forcing the strands into a parallel
configuration which is highly symmetric. This parallel scaffold was chosen based on the
understanding gained in our previous work which showed that the human telomeric G4
forming sequences use a conformation-selection mechanism where the relative
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population shift of the three possible scaffolds shift upon binding, resulting in an increase
in the population of the parallel scaffold, and a decrease of populations of the antiparallel
and/or hybrid scaffolds. 148 On the other hand, the c-KIT1 DNA G4 (Figure 13B;F) has
an anti-parallel scaffold with double chain-reversal and a long lateral stem loop at the 3’
region made of five nucleotides, two of which (A16 and G20) are capable of pairing.
There is also one non-G-tract guanine that is part of the core of stacked G-quartets and
the short single and dinucleotide loops of this c-KIT1 G4 are extremely flexible and show
extensive base flipping. Whereas the c-Myc DNA G4 (Figure 13C;G) has a hybrid
scaffold with a snapback motif that is adopted by the 3′-end GAAGG segment that forms
a stable diagonal loop containing a G(A-G) triad and caps the 3’ side of the G-tetrad. For
our DNA duplex system we use a GC rich DNA duplex (Figure 13D;G), rather than using
an oligonucleotide comprised of a polyethylene glycol linker able to fold into a hairpin as
used in the FRET melting temperature assay by Xu and coworkers, which we feel is a
more suitable comparison under physiological conditions.
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Figure 13. The initial configuration (A-D) and topology models of the simulation
systems (E-H). A&E: Duplex DNA, B&F: Human telomeric quadruplex G4 (PDB ID:
1KF1), C&G: c-KIT1 quadruplex (PDB ID: 4WO3), and D&H: c-Myc quadruplex
(PDB ID: 2MGN). 5’ and 3’ are indicated by red and blue spheres, respectively. K+ ions
are represented in yellow.
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3.1.5 Relevant studies. To date, a variety of studies have demonstrated using
molecular modeling and simulations as a powerful approach to identify structural details
at a molecular level. Hou et al. used this approach to probe the stability of six ligand-Gquadruplex DNA complexes structurally determined by experimental approaches 149. Many
of MD simulations studies are ligand binding studies that effectively provide mechanistic
insight into the binding of small molecules to G4 DNA 150-155. Information such as DNAligand binding free energy calculations, identification of ligand/G4 binding sites, and
ligand binding modes were successfully determined using a modeling system that utilized
the standard parm99 Amber force field using parmbsc0 parameters and a K + cation in the
center of the G-tetrads to neutralize the system152, 153, 156. Deng et. al resolved ligandbinding specificity using absolute free binding energy calculations for both c-MYC 157 and
human telomeric 158 G-quadruplex DNA . The work of Luo and Mu studied the binding of
small molecules to human telomeric G-quadruplex using all-atomic molecular dynamic
simulations159. Kumar and coworkers studied the binding of small molecules to G4 formed
by the c-MYC promoter147. Some studies, like that performed by Chatterjee and coworkers
have also had success performing an in silico screening on G4 structures formed by the cMYC oncogene
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. Further, the Lemkuls group has performed extensive work on the

binding of small molecules to the c-KIT1 promoter G4 using molecular dynamics
simulations161-163. In addition to small molecules targeting single G-quadruplexes,
Praadeepkumar and coworkers studied the binding of small molecules that stabilize
multiple G-quadruplex forming sequences including the c-MYC and c-KIT1 promoter
G4s164. Modeling studies have also produced insight into a variety of G-quadruplex
forming sequences. Research done on telomeric G4s have successfully calculated realistic
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intermolecular and relative binding energies as well as determined binding modes and
pathways. 155, 165, 166 Research performed by Liu and others extensively studied potassium
binding with human telomeric intra-molecular G-quadruplex using molecular dynamics167.
These studies provide invaluable insight into the model systems and strongly suggests the
importance of using atomistic simulations to rationalize biologically relevant
phenomena.152,

165

Even more, many biological studies have been performed beyond

computation that highlight the potential of targeting DNA G-quadruplexes with small
molecules like CX-5461, however there are very limited complex structures available.
3.1.6. Experiment goals. With these facts in mind, the goal of this study is to use
free ligand all atom molecular dynamics binding simulations to study the binding of CX5461 to the human telomeric, c-KIT1 and c-Myc G4s and a DNA duplex. Our post
simulation analysis will identify the major binding pose, binding mechanisms and binding
pathways of the CX-5461 complexes and provide novel insight as to how CX-5461 has
been experimentally shown to selectively bind to and stabilize these G4s. Through our
analysis we also address the order of stability of each system and features that differentiate
the binding of CX-5461 to the G4’s and the DNA Duplex which help to understand the
experimentally determined binding affinity and selectivity of CX-5461 to the G4 structures
over the duplex. With the interaction insights, we propose optimizations to CX-5461 that
may increase its interactions with G4s but decrease its interactions with the DNA duplex,
which may improve its anti-cancer capability with less reversed effects.
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3.2 Methods
3.2.1 Simulation methods overview. A full description of the methods used in this
study is provided in the Supporting Information. In brief, a total of nine systems were
constructed: three free ligand quadruplex-ligand complex systems (PDB ID’s: 1KF1,
4WO3, 2MGN), one free ligand DNA duplex-ligand complex system, the DNA only form
of each respective system, as well as a CX-5461 only system (Table 4). The DNA duplexligand system was constructed using a B-DNA duplex structure, sequence: d([GC]10)2,
using the Maestro program. The three DNA quadruplex-ligand systems were solvated
inside a water box of truncated octahedron with 10 Å water buffer. Cl- or K+ counter ions
were used to neutralize the system. The DNA fragments were represented using a refined
version of the AMBER DNA OL15 (i.e., parm99bsc0168 +χOL4169+ ε/ζOL1170+ βOL1171
updates). The water was represented using the TIP3P and the K+/Na+ model developed by
Cheatham group was used to represent the K+ ions.172 The standard AMBER protocol was
used to create the force field for CX-5461. This procedure included calculating the
molecular electrostatic potential (MEP) of the CX-5461 molecule at the HF/6-31G* level
after geometry optimization at the same theory level. Along with other parameters collected
from the AMBERGAFF290 force field, the MEP was used to identify the partial charges of
the CX-5461 atoms using Restrained Electrostatic Potential/RESP method with two stage
fitting173. Using AMBER DNA force fields are a highly effective and widely used in
nucleic acid simulations.174-177 This experiment was able to simulate the binding process
of the DNA G-Quadruplex (G4) stabilizer CX-5461, to a human telomeric G4 (PBD ID:
1KF1), a human c-KIT1 G4 (PBD ID: 4WO3), and a c-MYC promoter G4 (PBD ID:
2MGN),145-147 as well as a B-DNA fragment. 178 The AMBER GAFF2 force field of CX-
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5461 in Mol2 format is provided at the end of the supporting document. The detailed
protocol for these simulations follow an earlier study;179 where the AMBER 16
simulation package was used for the production runs of all four systems.90 Following the
Maxwell-Boltzmann distribution, atoms of the system were assigned different initial
velocities by use of random seeds after the energy minimization. Thirty independent
trajectories were run for each of the four complex systems to allow for better sampling of
binding poses and pathway. In order to equilibrate the system density, a 500 ns production
run at 300 K included a 1.0 ns molecular dynamics in the NPT ensemble mode (constant
pressure and temperature). During this production run the DNA and the ligand were under
Cartesian restraints (1.0 kcal/mol/Å), and 499.0 ns molecular dynamics in the NVT
ensemble mode (constant volume and temperature). Two or three representative
trajectories for each of four complex system were further extended into 1999.0 ns. A 2.0 fs
time step in the simulations was created using SHAKE180, which was able to constrain any
bond connecting hydrogen atoms. Long-range electrostatic interactions under periodic
boundary conditions (charge grid spacing of ~1.0 Å, the fourth order of the B-spline charge
interpolation; and direct sum tolerance of 10–5) were treated with the particle-mesh Ewald
method.181 The long range van der Waals interactions were based on a uniform density
approximation; the cutoff distance for short-range non-bonded interactions was 10 Å. Nonbonded forces were calculated using a two-stage RESPA approach.182 During this
approach, the short-range forces were updated every step whereas the long range forces
were updated every two steps. Using a Langevin thermostat with a coupling constant of
2.0 ps, the temperature was controlled and the trajectories were saved at 50.0 ps intervals
for analysis.
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Table 4
Molecular dynamics simulation runs.
Drug NPT
Total
No. No. No. Water
Box Size
NVT
DNA
ions
Initial eq.
time
Ligand run molecules
(Å)*
(ns)
Pose (ns)
(µs)
0
1
2
1420
1 Cl- 40.6
Free
1 1999
4
1
1(h-Tel)
0
2
4671
21 K+ 60.9
N/A
1 1999
4
2
1(c-KIT1)
0
2
3954
21
K+
58.1
N/A
1
1999
4
3
0
2
4843
23 K+ 61.9
N/A
1 1999
4
4 1(c-Myc)
2
4515
18 K+ 55.4
N/A
1 1999
4
5 1(Duplex) 0
27/
499
1(h-Tel)
1
8261
20 K+ 72.4
Free
1
19.5
6
3
/1999
28/
499
6371
20 K+ 67.0
Free
1
18.0
7 1(c-KIT1) 1
2
/1999
28/
499
1
5958
22 K+ 65.8
Free
1
18.0
8 1(c-Myc)
2
/1999
28/
499
5282
17 K+ 57.0
Free
1
18.0
9 1(Duplex) 1
2
/1999
1
Systems 1-4 refer to the free DNA-only systems, system 5 refers to the CX-5461 free
ligand simulation, systems 6-9 refer to the free DNA plus free ligand simulations (6:9:
Human telomeric (PDB ID: 1KF1), c-KIT1 (PDB ID: 4WO3), c-Myc (PDB ID: 2MGN)
and Duplex complexes, respectively).
*Triclinic box equivalent to the true truncated octahedral box
ID1

3.3 Results
3.3.1. Convergence analysis for the apo form systems. To validate the force
field used in our simulations, independent 2µs stability simulation runs carried out for
each apo form. We performed a root mean square deviation (RMSD) analysis which
compared the deviation of the DNA backbone in each snapshot to the initial structure.
The flat RMSD values showed that the ligand only or the apo DNA remained stable in
each simulation run and after taking the average of each run per system a figure is
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presented in Figure B1. Nonetheless, the three G4 systems showed a larger structure
deviation from the initial conformation (i.e., ~4Å of human telomeric G-quadruplex, ~3Å
of c-KIT1 G-quadruplex and ~5Å of c-Myc G-quadruplex) due to the fluctuation of nonG-tetrad parts. Next, we analyzed the last snapshots of each apo form simulation run
(Figure B2) and found that each the scaffold of each system was visually maintained
when compared to the initial structure. A deeper understanding of the RMSD values were
obtained through visual inspection of the apo form trajectories. For the human telomeric
system, there appears to be high flexibility at the 5’ terminal residue as well as for each of
the three, three residue, connecting loops. The c-KIT1 system showed high flexibility at
the 5’ terminal residues as well as the four connecting loops, ranging from 2 to 5 residues
long. The c-Myc system showed the greatest flexibility at the longer 5’ terminal segment
and also at the varied length connecting loops. The most notable difference of the last
snap shots was for the c-Myc system, where some residues of the longer and highly
flexible 5’ terminal segment stabilized on the G4 core which was consistent in both runs,
which is likely because the original PDB structure of this G4 contained a ligand and our
simulation runs allowed the DNA to relax into an apo form. Following this analysis we
took representative snapshots (Figure B3) for each of the apo DNA simulation systems:
human telomeric (A), c-KIT1 (B), c-Myc (C) G-quadruplexes, and DNA duplex (D).
Along with each representative trajectory is an order plot which shows that each system
maintained a backbone RMSD, the potassium ions in each G4 system maintained their
initial positions, and each systems MMPBSA energy relative to the initial snapshot
showed small fluctuations but the average remained the same overall.
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3.3.2. Convergence analysis for the holo form systems. A variety of post
simulation analyses were performed to ensure proper sampling and convergence was
reached in our simulations. First, we generated a plot showing the position of a single
atom of CX-5461 in each trajectory (Figure B4). Due to the clear distribution of binding
around the DNA in each system, we concluded there was a good sampling in each
system. Following this, the root mean square deviation (RMSD) of the DNA backbone
was calculated against the initial structure for the complex systems and the average of
each system was calculated and presented (Figure B5). The flat and small receptor
RMSDs in each system indicated the stability of the DNA structures during the
simulation period. Next, atom contacts between the DNA structure and CX-5461 were
calculated using a 3.0 Å cutoff (Figure B6). Here we defined a stable complex as a
complex with a number of atom contacts between the DNA and ligand greater than 30.
The stable contact number in this figure indicates the simulation systems reached a steady
state in all runs. With our analyses suggesting proper sampling and convergence, we
started looking at the binding poses. The last snap shots and a table summarizing each
system’s final binding poses are provided in the supporting document (Figures B7-B10;
Table B1). An additional stability analysis characterizing each systems geometry was
performed which will be discussed later (Table B2-B6).
3.3.3. Clustering analysis of the holo forms. Following the simulation runs, we
performed a k-means clustering to extract the major binding modes of each system. Each
system was grouped into three major structural families and represented by a centroid
structure for which each snapshot was most similar. The centroid structures along with
the structural families overall percentage is presented in Figure 14. In addition, two
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dimensional interaction diagrams along with top and side views of the most abundant
clusters of each system are presented in the supporting document (Figure B11 A-D) and
Figures B12-B13 compare the top and groove clusters for each system, respectively.
For the human telomeric complex system the top binding mode accounted for
37.8%, the bottom binding mode 20.8%, and the side binding mode 36.9%. Due to the
symmetry of the human telomeric G4, binding opportunities were roughly equal for the
top and bottom binding modes. This is clear when comparing the similar major binding
mode for the top and bottom modes and from the specific details gained from the two
dimensional interaction diagrams in Figure B11A. In the top binding mode CX-5461’s
rigid core (Figure 12) is parallel to the 5’ G-quartet and the entire CX-5461 molecule
interacts with each residue of the 5’ G-quartet (G2, G8, G14, and G20). In addition, it is
further stabilized by a full intercalation by terminal reside A1 and a hydrogen bond is
formed between the nitrogen of flexible side chain R1 and residue G8. In the bottom
binding mode, CX-5461 also stacks parallel with the 3’ G-quartet and interacts with each
of the residues of this G-quartet (G4, G10, G16, G22). In addition to these interactions,
flexible side chain R2 is further stabilized by two loops residues. First of which is residue
T5 which forms a partial intercalation around R2 and the second is residue A7 which folds
down toward the binding site and forms a hydrogen bond with a nitrogen of R2. In the
groove binding mode, each loop also provides equal binding opportunity due to the
identical sequence (TTA) and connections to the G4 core. From the most abundant pose
you can see the T11T12A13 loop is the primary interaction area where T12 forms a
hydrogen bond with a nitrogen of R1. Although part of the rigid core of CX-5461 is able
to stack inside a groove on the G4 core, it is evident that in this mode most of the core
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and all of R2 is exposed to solvent and forms less interactions than in the top and bottom
binding modes.
For the c-KIT1 complex system (Figure 14; Figure B11B) the top binding mode
accounted for 53.5%, the bottom binding mode 24.0%, and the side binding mode 15.7%.
The topology of the c-KIT1 G4 contains a short 5’ segment and a flexible 5’ face loop
(C11T12) which often stack on top of the 5’ g-tetrad. In the most abundant top biding pose
for the c-KIT1 system, the rigid core of CX-5461 stacks on top the 5’ terminal and
interacts with all four residues of the 5’ G-quartet (G2, G6, G10, G13). Further stabilization
is provided through interactions with terminal residue A1 which fully intercalates CX5641 onto the G4 core. It also interacts with both residues of the 5’ face loop where C11
flips upward to stabilize the interaction. The most abundant bottom binding mode shows
a much different binding pose. The c-KIT1 G4 has a AGGAG 3’ terminal loop for which
A16 and G20 base pair directly under the 3’ G-quartet and a smaller GGA loop is formed.
In the most abundant bottom binding pose, the A16G20 base pair blocks CX-5461 ability
to interact with the 3’ G-quartet. Instead, CX-5461 interacts with each residue of the
G17G18A19 3’ loop where flexible side chain R1 folds upward to interact with the residue
G18 through hydrogen bonding. In this mode, R1 also interacts with residue G20, whereas
R2 is entirely exposed to solvent and unbound. For the most abundant groove binding
mode for the c-KIT1 system we observe a pose similar to the bottom binding mode. Here
we see that one residue, C11, of the 5’ face loop flips outward and interacts with CX-5461
and T12 residue of this same loop also interact with CX-5461. In this mode we also see
that while R2 is flipped outward and entirely exposed to solvent, R1 stacks along the G4
core, interacting with core residues (G10, G13, G21, G22).
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For the c-Myc complex system (Figure 14; Figure B11C) the top binding mode
accounted for 59.6%, the bottom binding mode 9.5%, and the side binding mode 26.7%.
The topology of the c-Myc system has a several unique features. One of which is the
highly flexible three residue (T1G2A3) 5’ terminal segment which adopts several positions
including being flipped completely outward and stacked on top of the 5’ G-quartet. The
dynamic between these two positions is critical for the most abundant top binding pose
for the c-Myc system. In this mode, CX-5461 is fully intercalated onto the 5’ G-quartet
due to the direct stacking of the G2 residue of the 5’ segment. In more detail we see that
T1 is stacked on top of G2 and that A3 is flipped outward allowing its initial position to be
occupied by CX-5461 while both residues still interact with CX-5461. Further, as
mentioned this interaction allows for a full intercalation where CX-5461 also interacts
with all four residues of the 5’ G-quartet (G4, G8, G13, G17). One additional interaction
occurs between loop residue A12 which flips upward to enhance the binding interactions
of this pose. A second unique feature of the c-Myc topology is the four residue
G20A21A22G23 3’ face loop which connects residues G19 and G24 of the 3’ G-quartet,
where G24 is the 5’ terminal residue. Evident from the most abundant bottom binding
pose, this 4 residue loop directly blocks CX-5461’s access to the 3’ G-tetrad which
prevents bottom intercalation. Due to this, in the most abundant pose the flexible side
chain R1 of CX-5461 is a stacking onto the DNA backbone of this loop where its positive
charge is able to interact with residues G20, A21, A22 and G23. However, R2 is completely
exposed to solvent in this mode. In the groove binding mode, a similar binding mode to
the bottom binding mode is observed where flexible side chain R1 folds upward and the
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positively charged nitrogen hydrogen bonds with base T7 while maintaining interactions
with bases G8 and G9.
For the duplex complex system (Figure 14; Figure B11D) the top binding mode
accounted for 3.8%, the bottom binding mode 4.5%, and the groove binding mode
25.7%. Although the top and bottom binding modes are reported to consistency,
terminals of DNA are rare in the human body so we chose to focus our analyses on the
groove binding mode due to its physiological relevance. Here we see the flexible side
chain R1 of CX-5461 binding inside the groove of the duplex and forms a hydrogen bond
with residue C6, while R2 and the core are exposed to solvent.
Overall, it was clear that for each G4 system the top binding mode was most
abundant and that in these poses, the DNA’s interaction with rigid core of CX-5461 was
most a key factor in stable binding. In the duplex system, groove binding was most
abundant and the flexible side chains of CX-5461 were most involved in stable binding
for this system. However, we feel the most significant differences in the major binding
modes are attributed to structural differences and their impact on CX-5461 ability to
interact with the G4 core. This was made clear when comparing the binding modes of the
bottom binding poses to the more favorable top binding pose. Moreover, we observed
very similar pattern of binding interactions between our G4 side binding and the duplex
groove binding. With this in mind we wanted to explore energetic implications of these
differences in binding and determine if our predictions about the binding interactions
matched the binding energies.
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Figure 14. Major binding modes of CX-5461 binding to the human telomeric G4 (PDB
ID: 1KF1), c-KIT1 G4 (PDB ID: 4WO3), c-Myc G4 (PDB ID: 2MGN) and duplex DNA.
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3.3.4. MM/PBSA binding energy analysis. Of the four systems, the top
intercalating mode of the human telomeric DNA G-quadruplex (1KF1) was shown to be
the most energetically favorable binding mode (Table 5). Calculated to be -37.0 kcal/mol,
this binding mode was -3.4 kcal/mol more favorable than the bottom binding mode (-33.6
kcal/mol) for the human telomeric G4 system, and -21.7 kcal/mol more favorable than the
side binding mode (-15.3 kcal/mol).
For the c-KIT1 G4, the top binding mode, calculated to be -33.1 kcal/mol, was most
energetically favorable of this system. This binding mode was -11.1 kcal/mol more
favorable than the CX-5461’s bottom binding pose (-22.0 kcal/mol) in the c-KIT1 G4 and
-16.6 kcal/mol more favorable than the side binding pose (-16.5 kcal/mol). However when
comparing c-KIT1’s top binding pose to the human telomeric G4’s top binding pose, the
human telomeric G4 has a more favorable binding energy by -3.9 kcal/mol.
For the c-Myc G4 system, the top binding mode was also most energetically
favorable calculated at -32.6 kcal/mol. The top binding mode was more favorable than the
bottom binding mode (-15.5 kcal/mol) by -17.1 kcal and more favorable than the side
binding mode by -14.8 kcal/mol. When comparing c-Myc’s top binding pose to the human
telomeric G4’s top binding pose, the human telomeric G4 has a more favorable binding
energy by -4.4 kcal/mol.
The duplex groove binding mode was the least energetically favorable, measuring
-15.0 kcal/mol. This binding energy of the duplex groove mode was comparable to the side
binding modes of the G4 systems: human telomeric (-15.3 kcal/mol), c-KIT1 (-16.5
kcal/mol), and c-Myc (-17.8 kcal/mol). The bottom binding mode of the c-Myc system (-
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15.5 kcal/mol) was also comparable to the duplex systems groove binding mode. These
results suggest that CX-5461 is selective to DNA G-quadruplex systems over DNA duplex
because each of the most favorable binding poses for the G4 systems is at least twice as
energetically favorable as the duplex groove binding mode. Further the less favorable MMPBSA binding energy of the G4 systems suggests that side binding may be an intermediate
state.
CX-5461’s average MM/PBSA binding energy over the major poses were
calculated for the human telomeric (-28.6 kcal/mol), c-KIT1 (-23.9 kcal/mol), c-Myc (22.0 kcal/mol) G4s, and DNA duplex (-15.0 kcal/mol) systems. The binding energy was
broken down into van der Waals (VDW), hydrophobic interactions (SUR), electrostatic
interactions (GBELE), and the conformational energy change induced from the complex
formation (CONF) (Table 5). From the table it is clear that the hydrophobic interactions
(ΔSUR) contribute the most to the total energy. As expected, the top intercalation binding
modes have the most energetically favorable hydrophobic interactions and are much more
favorable than the duplex systems groove binding mode.
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Table 5
MM-PBSA binding energy of CX-5461 binding to the human telomeric Gquadruplex (1KF1), c-KIT1 G-quadruplex (4WO3), c-Myc G-quadruplex
(2MGN), and duplex DNA in each of the major binding modes.
Sys.

BS

ΔVDW1

ΔSUR

ΔPBELE

ΔCONF

ΔTOT

ΔΔE2

ΔT
3
m

30
h-Tel T -9.3±6.3 -32.9±3.1 10.5±1.3 -5.4±3.8 -37.0±3.9 0
B -3.5±5.9 -22.3±2.4 6.0±3.8 13.8±4.6 -33.6±0.7 3.4
-15.3±1.5 21.7
S -4.5±3.6 -23.7±2.0 11.3±2.3 1.5±8.0
27
c-KIT1T -4.4±0.9 -25.4±0.5 8.2±0.6 -11.5±2.7 -33.1±0.7 3.9
B -2.0±1.6 -11.0±0.7 5.1±1.0 -14.1±2.3 -22.0±0.4 15
S -3.0±1.9 -12.8±0.7 7.1±1.4 -7.8±11
-16.5±0.6 20.5
25
c-Myc T -13.7±4.3 -35.2±1.5 16.4±0.7 -0.1±3.9 -32.6±4.7 4.4
B -4.3±0.8 -16.0±0.2 9.0±0.5 -4.3±4.7 -15.5±1.0 21.5
S -5.3±6.2 -25.7±3.0 15.9±1.6 -2.7±1.4 -17.8±2.5 19.2
-13.8±3.9 23.2 10
Dup. G -2.1±41.2 -23.1±2.1 8.2±2.3 3.2±3.9
-16.1±2.7 20.9
T -4.3±0.8 -15.4±0.7 3.8±0.9 0.1±0.9
B -3.8±1.2 -15.9±1.8 4.6±2.3 0.02±0.8 -15.1±1.8 21.9
1
The parameters in this table are reported in units of kcal/mol.
ΔVDW = Change of VDW energy in gas phase upon complex formation
ΔSUR = Change of energy due to surface area change upon complex formation
ΔEBELE = Change of GB reaction field energy + gas phase Elec. energy upon complex
formation
ΔCONF = Change of conormational energy upon complex formation
ΔTOT = ΔVDW +ΔSUR + ΔEBELE + ΔCONF Change of potential energy in water
upon complex formation
Sys. refers to system and BS refers to binding site: Top (T), Bottom (B), Side (S), or
Groove (G).
2
ΔΔE2= (ΔTOT -(-37.0))
3
Experimental melting temperature increase (in Kelvin) of each system with 10 µM CX5461 from a FRET melting temperature assay1. Values are estimated based on the figure
in the literature.

3.3.5. Markovian state model overview. To characterize the binding of CX-5461
to the DNA G4s and duplex we performed a Markovian State Model (MSM) analysis.
We present the MSM along with representative trajectories and order plots for each of the
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thermodynamically favorable state in each system: human telomeric (Figures 15-17), cKIT1 (Figures 18-19), c-Myc (Figures 20-21), and duplex (Figure 22;B14). MSMs can
be built from MD simulation data and are a comprehensive statistical approach used to
create understandable yet high-resolution models of the intrinsic kinetics of a system.183
Our MSM analysis follows a similar procedure to that of our previous work184 which also
examined the binding pathways and kinetic information of G-quadruplex structures. Our
implied timescales of each cluster for all lag times of each system are presented in Figure
B15. Due to choosing to cluster into a handful of “macrostates” and directly and skipping
over the experimentally unverifiable thousand “microstates”, the expected convergence
time of the implied timescales should be significantly greater than that of a model with a
greater number of clusters. This results in a coarser grained model that trades finer detail
for greater experimental testability and easier human understanding 183, 185. It is likely that
directly clustering into “macrostates” still maintains the integrity of the MSM as
verification through the Chapman-Kolmogorov test (Figure B16A-D) indicates that the
model closely resembles the observed simulation data. Two dimensional network models
are also presented in the supporting document for each system (Figure B17).
3.3.6. Markovian state model for the human telomeric system. For the human
telomeric system, there were four major parallel pathways were observed for CX-5461:
unbound to top binding, unbound to bottom binding, and unbound to side binding as an
intermediate state before transitioning to either a top or bottom binding pose. The mean
first passage times between the four states are shown in Figure 15 where green arrows
indicate the more likely transition while blue arrows indicate a less likely transition. The
top (37.8%) and bottom (20.8%) binding poses are the thermodynamically favorable
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binding states which collectively make up approximately 58.5% of the simulation. Our
calculated first mean passage times indicated that the pathway from unbound directly to
the top binding state is slightly faster (3.3 µs) than unbound directly to the bottom
binding state (4 µs) and both the transition states starts unbound and going from the side
to top (1.2 µs+3.1 µs=4.3 µs) and side to bottom (1.2 µs+5.7 µs=6.9 µs) transition states.
The approximate interstate flux for unbound to top binding was 1:15, unbound to side
binding was 3:5, unbound to bottom binding was 2:3, side binding to top binding was
unidirectional from side binding to top binding, and side binding to bottom binding was
20:1.

Figure 15. The mean first passage times between the four states (unbound, side transition,
top, and bottom) of the human telomeric DNA G-quadruplex and CX-5461 complex
system.
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We present two representative trajectories which characterize the binding of the
most thermodynamically favorable states, one trajectory showing the top unbound to top
binding mode and one showing the unbound to side binding transition state ending in a
top binding mode. We do not include an unbound to bottom or transition state to bottom
binding mode trajectory in the main text due to the structural symmetry of the human
telomeric system. However, an additional trajectory of CX-4561 in the bottom binding
mode is reported in the supporting document (Figure B18). The representative top
binding mode of CX-5461 shows a clear induced fit binding mechanism (Figure 16). At 2
ns the central chromophore of CX-5461 makes initial contact with loop residue A13. At
19 ns, CX-5461 repositions into a top staking mode on top of the first G4 layer. At 101
ns, A1 flips outward making room for CX-5461 to better reposition on the top G4 layer.
By 128 ns residue A1 flips back and binds to the top of CX-5461, allowing CX-5461 to
intercalate between A1 and the top G4 tetrad where it remained until the end of the 2000
ns simulation. The order parameters indicate the system was stable throughout the
trajectory. This quadruplex was able to maintain ~8, ~10, ~8 hydrogens in the top,
middle, and bottom layers, respectively. The drug-base dihedral angle remained small
after the binding of CX-5461. The ligand RMSD indicated it was stable by the small and
flat RMSD of ~2.5 Å. The DNA backbone was generally maintained with slight changes
concurrent with the most prominent binding changes of the complex during the
trajectory, but remains stable overall maintaining a RMSD of ~15 Å after the final
binding pose is achieved. The K+ cations remained stable, keeping ~4 Å between them.
The MM-PBSA binding energy revealed slight fluctuations but a binding energy of ~-30
kcal/mol was maintained for the majority of the trajectory. In the transition state
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trajectory (Figure 17), the final binding pose is similar to the representative top binding
pose however until ~88 ns CX-5461 was bound to the T11T12A13 loop before intercalating
into the top of the 5’ G-quartet. Similar order parameters were observed for this
trajectory, however the time to stability was slightly longer in this case due to the
transition.
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01 ns: Random Searching

02 ns: Initial Contact

101 ns: Top Stacking

128 ns: Intercalation

1058 ns: Intercalation

2000 ns: Intercalation

Figure 16. Snapshots from the representative trajectory of the top binding mode of the
human telomeric G4, run 13, including an order parameter plot. Illustrated in the plot is
the breaking and reforming of hydrogen bonds per G4 layer (Top/Red, Middle/Green and
Bottom/Blue), drug-base dihedral angle, ligand(black)/DNA(red) RMSD (Å) with
reference to the final structure, ligand center to DNA center distance(black) and K+ to K+
distance(red), and the MM-GBSA binding energy (ΔE in kcal/mol). 5’ and 3’ of the DNA
chain are indicated by a red and blue ball, respectively. K+ ions are indicated by yellow
spheres.
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1 ns: Random Searching

28 ns: Side Binding

89 ns: Intercalation

301 ns: Full Intercalation

391 ns: Intercalation

1943 ns: Top Stacking

Figure 17. Snapshots from the representative trajectory of the top binding mode of the
human telomeric G4, run 05, including an order parameter plot. Illustrated in the plot is
the breaking and reforming of hydrogen bonds per layer(Top/Red, Middle/Green and
Bottom/Blue), drug-base dihedral angle, ligand(black)/DNA(red) RMSD (Å) with
reference to the final structure, ligand center to DNA center distance(black) and K+ to K+
distance(red), and the MM-GBSA binding energy (ΔE in kcal/mol). 5’ and 3’ ends of the
DNA chain are indicated by a red and blue ball, respectively. K+ ions are indicated by
yellow spheres.
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3.3.7 Markovian state model for the c-KIT1 system. The c-KIT1 G4 system
shows three major parallel pathways leading to one thermodynamically favorable top
binding state: unbound to top binding, and unbound to side binding as an intermediate state
before transitioning to a top binding pose, and unbound to bottom binding before
transitioning to a side binding pose and finally transitioning to a top binding pose. The
mean first passage times between the three states are shown in Figure 18 where green
arrows indicate the more likely transition while blue arrows indicate a less likely transition.
Each of the pathways led to a thermodynamically favorable top binding state which
accounted for 53.5 % of the simulation period and occurred in 1.2 µs. The unbound to side
to top pathway was the next fastest totaling 2.7 µs. The slowest pathway was from the
unbound state to the side and finally ending in a top binding mode which totaled 6.8 µs.
Important to note is that we believe the MSM determined that the bottom binding mode is
not a thermodynamically favorable state in this system because of the limited simulation
period, however we expect that if the simulations were extended further, a
thermodynamically favorable bottom binding site would be seen. The approximate
interstate flux for unbound to top binding was 3:4, unbound to side binding was 3:4,
unbound to bottom binding was 1:10, side binding to top binding was 1:30, and side
binding to bottom binding was 1:50, and top binding to bottom binding was 1:4.

80

Figure 18. The mean first passage times between the four states (unbound, side transition,
top, and bottom) of the c-KIT1 DNA G-quadruplex and CX-5461 complex system.

Since the only thermodynamically favorable state is the top binding mode, we
present one representative trajectory of this mode (Figure 19) in the main text. For the top
binding mode of the c-KIT1 G4 the simulation begins with random searching of CX-5461.
By 4 ns, CX-5461 makes initial contact with the c-KIT1 G4 by interacting with residue
A5. This interaction continues until CX-5461 moves to the top of the G4 at 230 ns, where
the central chromophore of CX-5461 binds to residue G6 of the top G4 quartet. At 230 ns
the 2-methylpyrazine side chain of CX-5461 makes the first interaction with the G4 side
loop residue C11 and this interaction continues until 383 ns when residue C11 flips upward
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and guides the interaction of CX-5461 deeper into the top binding pocket of the G4,
allowing it to become sandwiched between bases A1 and G6. At 413 ns the reside C11
flips outward and base T12 is able to bind to flip over and bind on top of CX-5461, along
with residue A1 which has maintained its sandwiching interaction with CX-5461 since 383
ns. This binding pose and interactions are maintained for the remainder of the 2000 ns
trajectory. The A1 and A12 pair maintained ~2 hydrogen bonds, the top, middle and bottom
G4 layers maintained 8, 10, and 5 hydrogen bonds, respectively. The G17 and A19 base
pair did not form hydrogen bonds in this run. Around 400 ns the drug-base dihedral angle
as well as MMPBSA binding energy stabilizes, with very minimal fluctuations; this finding
is consistent with the timing of CX-5461 positioning into the final binding pose for this
trajectory. The ligand RMSD and ligand center to DNA center distance stabilize around
150 ns which is concurrent with the ligand repositioning from the side to the top of the
quadruplex where it remains for the length of the trajectory. The DNA RMSD and K +
cation distance remain stable throughout the trajectory. There additional trajectories
presented in the supporting document for the top (Figure B19) and bottom binding modes
(Figure B20-21) which show CX-5461 binding to both the outside of the bottom loop as
well as inside of the bottom loop, but not actually interacting with the G4 core. In addition
to this, a trajectory is presented in the supporting document to show the side to top binding
mode (Figure B22).
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1 ns: Random Searching

4 ns: Side Loop Interaction

144 ns: Top Stacking

383 ns: Sandwiched

413 ns: Full Intercalation

1993 ns: Intercalated

Figure 19. Snapshots from the representative trajectory of the top intercalating binding
mode of the c-KIT1 G4, run 19, including an order parameter plot. Illustrated in the plot
is the breaking and reforming of hydrogen bonds per layer (5’ Face/Red, Top GTetrad/Cyan, Middle G-Tetrad /Blue, Bottom G-Tetrad /Black, and 3’ Face/Green), drugbase dihedral angle, ligand(black)/DNA(red) RMSD (Å) with reference to the final
structure, ligand center to DNA center distance(black) and K+ to K+ distance(red), and the
MM-GBSA binding energy (ΔE in kcal/mol). 5’ and 3’ of the DNA chain are indicated
by a red and blue ball, respectively. K+ ions are indicated by yellow spheres.
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3.3.8. Markovian state model for the c-Myc system. For the 2MGN system,
three major parallel pathways were observed: unbound to top, unbound to bottom, and
unbound to side transition and ending in a top binding mode. Unique to this system, the
bottom binding pose appears to be highly unstable and likely acts as an off pathway
intermediate state where CX-5461 binds to the bottom from an unbound state and once
again goes back to the unbound state and follows one of the other pathways leading to the
thermodynamically favorable top binding mode. The mean first passage times between
the states are shown in Figure 20 where green arrows indicate the more likely transition
while blue arrows indicate a less likely transition. The top (59.6%) and bottom (9.5%)
binding poses collectively make up approximately 69% of the simulation. The transition
from unbound directly to the top binding state (1.4 µs) is slightly faster than from
unbound to the top binding state through the side transition state (2.4 µs). Transition from
the unbound to the bottom binding pose is significantly slower calculated to be 16.7 µs.
The approximate interstate flux for unbound to top binding was 1:5, unbound to side
binding was 1:1, unbound to bottom binding was 1:4, and side binding to top binding was
1:3.
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Figure 20. The mean first passage times between the four states (unbound, side transition,
top, and bottom) of the c-MYC DNA G-quadruplex and CX-5461 complex system.

The interaction between the c-MYC G4 and CX-5461 is particularly interesting
because of the clear use of a base flipping mechanism by both the terminal residues, T1,
G2, and A3, but also the loop residue A12 (Figure 21). The first interaction of CX-5461 to
the c-MYC promoter G4 was at 1 ns where it made contact with the residues of the 5’
terminal. At 2 ns, the terminal residue A3 had already flipped on top of CX-5461 and
sandwiched it onto the top G-quartet; simultaneously, the methyl diazepane side chain of
CX-5461 made interaction with the loop residue A12. At 6 ns loop residue A12 has flipped
on top of CX-5461, which then fully intercalated into the top binding pocket of the c-MYC
G4, being stabilized by both residues A3 and A12. This interaction remained until 1136 ns
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when terminal residue T1 flipped over and joined residues A3 and A12 binding on top of
CX-5461. At 1742 ns terminal residue T1 flipped up again, and the ligand remained
intercalated into the interface for the remainder of the trajectory. The final binding pose
that CX-5461 maintained for the majority of the trajectory involved residues A3 and A12
intercalating the drug between residues G4, G17, and G8. The A3 and A12 base pair
maintains ~2 hydrogen bonds, the top, middle and bottom G-quartet maintain ~8, ~ 9, and
~5 hydrogen bonds, respectively; the G20, A22 and G23 base pairing also maintained ~2
hydrogen bonds. The drug-base dihedral angle and MMPSBA binding energy is roughly
maintained over the trajectory with a slight decrease after 1200 ns, consistent with the drugs
final binding pose of full intercalation. The DNA and ligand RMSD, drug center to ligand
center, and K+ cation distances are maintained throughout the majority of the trajectory.
There additional trajectories presented in the supporting document for the top (Figure B23)
and bottom binding modes (Figure B24-25) which show CX-5461 binding to both the
outside of the bottom loop as well as inside of the bottom loop, but not actually interacting
with the G4 core. In addition to this, a trajectory is presented in the supporting document
to show the side to top binding mode (Figure B26).
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0 ns: Random Searching

1 ns: Initial Interaction

2 ns: Sandwiched

6 ns: Ligand Sandwiched

1136 ns: Full Intercalation

1993 ns: Intercalated

Figure 21. Snapshots from the representative trajectory of the top intercalating
binding mode onto the c-Myc G4, run 14, including an order parameter plot. Illustrated in
the plot is the breaking and reforming of hydrogen bonds per layer (5’ Face/Red, Top GTetrad/Cyan, Middle G-Tetrad /Blue, Bottom G-Tetrad /Black, and 3’ Face/Green), drugbase dihedral angle, ligand(black)/DNA(red) RMSD (Å) with reference to the final
structure, ligand center to DNA center distance(black) and K+ to K+ distance(red), and the
MM-GBSA binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by
a red and blue ball, respectively. K+ ions are indicated by yellow spheres.
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3.3.9. Markovian state model for the duplex system. The MSM plot of the
duplex system and mean first passage times are presented in Figure B14 where green
arrows indicate the more likely transition while blue arrows indicate a less likely
transition. This plot shows the major pathways for the duplex system include one
thermodynamically favorable groove biding state (25.7%) as well top and bottom states
that end up in a groove binding mode. Since the groove binding mode is the only one of
physiological relevance for a long chromosome DNA, pathways leading to this mode are
discussed here. The pathway from unbound directly to the groove binding state is slightly
faster (2.0 µs) than from unbound to the transition states (top: 4.7 µs or bottom: 5.0 µs)
leading to the groove binding and is significantly more abundant. The representative
trajectory for the groove binding mode of CX-5461 to the DNA duplex is shown in
Figure 22. Clear from the representative snap shots, CX-5461 binds to the groove around
35 ns with slight repositions until fully relocating to another groove binding site at 845
ns. Although minor adjustments are seen, CX-5461 remains in this binding pose for the
remainder of the 2000 ns trajectory. The order plot shows changes concurrent with the
repositioning of CX-5461, where each parameter shows fluctuations until ~850 ns where
the final, stable binding pose is achieved. After 850 ns the ligand and DNA RMSD
maintains 30 Å and 10 Å, respectively. The drug center to DNA center distance is ~15,
and the MMPBSA binding energy is roughly -15 kcal/mol. Interestingly, in that
simulation run we observed CX-5461 scaling the surface of the DNA duplex, unable to
find a stable binding pose, repositioning around the grooves of the DNA duplex while
maintaining interaction during the entire binding process. Three additional trajectories for
this binding mode is presented in the supporting document (Figure B27-B29).
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01 ns: Searching

38 ns: Initial
binding

845 ns: Groove
binding

1997 ns: Groove
binding

Figure 22. Snapshots from the representative trajectory of the bottom binding mode of
the DNA duplex system, run 12, including an order parameter plot. Illustrated in the plot
is the ligand(black)/DNA(red) RMSD (Å) with reference to the final structure, ligand
center to DNA center distance(black) and the MM-GBSA binding energy (ΔE in
kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and blue ball, respectively.
K+ ions are indicated by yellow balls.

3.3.10. Geometry characterization. The geometry of the inter G4 layers from the
MD simulations is an area that has not yet been thoroughly studied despite literature
suggesting that the H-rise and H-twist geometry parameters were the most important
parameters to analyze the G4s overall structure. Characterizing these parameters is
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important because despite a number of works defining duplex DNA, there has been little
research into the helical rise and rotation of the quadruplex structure from molecular
dynamic simulations. We first performed a geometry analysis on both the apo and holo
forms to validate the parameters set for our simulation systems and to gain insight into the
overall geometry of the system (Table B2), which is a technique that has been successfully
implemented into our previous works184,

186

. Helical B-DNA is commonly defined by

maintaining average values of 3.32 Å and 34.3° for H-rise and H-twist, respectively. The
results of the H-rise and H-twist helical geometry parameter analysis revealed comparable
values for each of the systems being analyzed, providing quantitative support that the
helical structure was maintained throughout the simulations. Specifically, we identified the
average values for the H-rise (~2.6 Å) and H-twist (~20 Å) of the bases within the three
quartets of each G4 system and reproduced an average value for the rise parameter (~3.5
Å). In this work, it is clear that the H-rise and H-twist in the G-quadruplex are smaller than
those in standard B-DNA (3.32 Å and 34.3° for H-rise and H-twist). The G4 geometry
analysis in this study is supported by a recent bioinformatics study on 74 G-quadruplex
structures in the PDB databank which showed the distribution of the twist angle between
the two adjacent G-quartets for bimolecular parallel G-quadruplexes is ranged from 10º to
35º with a maximum at 31º±3º.187 By comparing the apo and holo forms, it is clear that
the binding of CX-5461 on the top and bottom of the each G-quadruplex did not change
these parameters much. Thus, we conclude that ligand binding can slightly modulate the
G-quadruplex inter-layer geometry. We also calculated base pair-axis, base pair-step, and
paired base-base parameters, as detailed in the method section, to characterize the duplex
geometry in the DNA only system versus in the most favorable groove binding pose (Table
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B3-B5). The values from the groove binding system generally agree with the values from
the DNA only simulation. For example, the DNA only simulation has average values of
~3.3 Å and ~35° for H-rise and H-twist, respectively. Whereas the groove binding mode
has average values of ~3.3 Å and ~35° for H-rise and H-twist, respectively. This is also
supported from the DNA backbone dihedral angle and pucker calculations (Table B5):
although there are some subtle differences, the majority of values are close to each other.
The hydrogen bond networks of the major binding modes of the G4 systems are presented
in Figures B30-B32 which show subtle differences.
3.3.11. Root mean square fluctuation analysis. The RMSF plots for each
system as well as a topology model which shows the position of each residue for which
the RMSF was calculated and presented in Figure 23. In each data set three large (~5 Å)
peaks were identified which correspond to three loops connecting the G-quartets: T5T6A7,
T11T12A13, and T17T18A19. Evident form the data here, the apo form has higher overall
fluctuations when compared to the complex systems. Overall, there are two pronounced
differences in the data series. The first is the lower fluctuations of the T11T12A13 loop in
the apo form simulation run, which may be due to this loop frequently flipping outward
to clear room for CX-5461 binding. The second is in the bottom binding pose where the
fluctuation of the T17T18A19 loop has significantly decreased fluctuation in residues T17
and T18, which may be due to a stabilizing effect because of CX-5461 directly interacting
with residue G16 in this binding mode. In addition we see here that the terminal residues
have roughly equal fluctuations due the structure symmetry of the G4. In the c-KIT1
systems the major peaks corresponded to residues of the connecting loops: A5, C9, C11,
T12 and G17, G18 and A19. Overall, the apo form trajectory had higher fluctuations than the
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complex systems indicating that CX-5461 binding slightly reduced the overall
fluctuations at these peaks. The once exception was at loop C11, T12 where the top binding
mode has this region with higher fluctuations. This is due to this loop flipping upward
and forming a hydrogen bond between R1 of CX-5461. Here we clearly see a difference
in the terminal residues where the 5’ terminal is significantly higher than the 3’ terminal,
which is likely due to the fact that the 3’ terminal is actually a residue of the 3’ G-tetrad
whereas the 5’ terminal is a free residue. There were 5 major peaks identified for the cMyc systems corresponding to residues T1-A3, T7, T10-A12, T16, and A21. Each residue
showing significant fluctuation was either a part of the large 5’ terminal segment (T1, G2,
A3), or a part of a connecting loop. In the c-Myc systems, the RMSF values were
comparable in each peak except for the T10, G11 and A12 region. The top binding mode
had a high fluctuation at residue T10 but lower fluctuations at G11 and A12, this is likely
due to this loop flipping upward to stabilize the binding of CX-5461. Where the higher
fluctuations of T10 are a result of the further distance travelled to flip upward compared to
G11 which flips outward and A12 which directly binds to CX-5461. The bottom system
had the largest fluctuation at T10 and G11 which flip outward during the simulation and the
receptor only system had equal fluctuations at residues T10, G11 and A12 which are also
flipped outward. The terminal residues are most notably different here where the long 5’
segment is highly flexible (5-6 Å) and the 3’ terminal, which is a part of the 3’ G-quartet
has very low fluctuations (~1 Å). The duplex DNA systems (grey and black) showed
peaks at residues G1, C10, G11, and C20, which are the terminal residues of the double
helix. Overall, we see that the human telomeric G4 loops have the highest fluctuations of
all systems which may help to explain the less favorable binding energy of the side
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binding modes compared to the other systems and the fluctuations of the apo G4 forms
are larger than the complex systems, suggesting that CX-5461 stabilizes the G4 DNA
upon binding.
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Figure 23. The root mean square fluctuation (RMSF) plot of the 11 systems (receptor
only, plus top and bottom binding modes of 1KF1, 2MGN, and 4WO3, groove binding
mode of the duplex system) with topology include on the right for reference. Standard
deviations are represented by error bars.
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3.4 Discussion
DNA G-quadruplexes (G4s) are over represented in a wide variety of cancers
making them a prime therapeutic target. 188 Stabilizing G4s of cancerous cells has
become a novel therapeutic technique that has been shown to inhibit cancerous cell
growth and replication leading to the cancerous cells death. 189 A promising new anticancer medication, CX-5461 is in in Phase I/II clinical trials for advanced hematologic
malignancies and cancers with BRCA1/2 deficiencies 117. Experimental evidence
identified CX-5461’s specific roles at G4s as the ability to bind to and stabilize G4
structures in human cancer cell lines, increase the number of G4 sites, as well as
selectivity bind to G4 structures on the human genome.117 These properties are extremely
advantageous for cancer therapeutics and evident from recent work CX-5461 is a
promising therapeutic agent for a variety of targets, however the detailed binding mode
and mechanism for which CX-5461 interacts with the G4 structures remains elusive. Our
analyses sought to characterize the binding of CX-5461 to the human telomeric, c-KIT1,
c-Myc G4s as well as a DNA duplex to provide insight into the binding process and help
to explain the experimentally reported order of binding induced stability.
Our simulation analysis identified three major binding features conserved in each
G4 system. First, we observed that 5’ intercalation was the most thermodynamically
favorable binding mode. This was evident from the MM/PBSA binding energy (Table 5)
and trajectory clustering (Figure 14). Second, the Markovian State Model (MSM) of each
G4 system revealed that there were multiple parallel pathways all leading to the
thermodynamically favorable top intercalation mode (Figures 15, 18, 20). Each of which
include a direct pathway from the unbound state to top binding as well as indirect
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pathways which could be using side binding as an on-pathway intermediate state. The
lower MM/PBSA binding energies of the side binding modes (Table 5) provide
thermodynamic support of the side binding intermediate states. The third common
binding feature was that the top binding mode of each system clearly were not achieved
through the use of a lock-key mechanism. Instead, each G4 system demonstrated the use
of a combination of the induced fit and conformational selection mechanisms. In more
detail, our apo form simulations (Figure B2-3) show that because of the short flexible
segments at the 5’ face of the G4’s there are some instances of base flipping observed for
both the 5’ terminal and 5’ face loop residues. However when CX-5461 binds, the
population is shifted toward the population which these bases stabilize and stack onto the
G4 core or CX-5461 which clearly shows evidence of a conformational-selection
mechanism. In addition, the most thermodynamically stable state is only achieved by a
base flipping insertion mechanism where terminal and side loop residues flip outward to
make room for CX-5461 insertion followed by the bases flipping back to make contact
with CX-5461, which demonstrated the use of an induced fit binding mechanism not
observed in the apo form. A clear example is the interaction between the c-Myc G4 and
CX-5461 which shows the use of a base flipping mechanism by both the terminal
residues, T1, G2, and A3, and also the loop residue A12 (Figure 21), which is supported
by the RMSF (Figure 23) and 2D interaction diagrams (Figure B11). Therefore, although
there are structural differences between the G4s, these same general binding
characteristics of CX-5461 are conserved which we suggest could be applicable to other
targets not studied here.
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Three notable differences were also extracted from our simulation analysis. It
was evident that the structural features of each system caused subtle differences in
binding modes (Table B7), binding energies (Table 5), and MSMs (Figures 15, 18, 20).
First, the human telomeric system’s structural symmetry on the 5’ and 3’ faces allowed
equal binding opportunities for both sites. The human telomeric system was the only
MSM to have parallel pathways leading to the bottom binding pose as a
thermodynamically favorable state (Figure 15), and the only system to have the binding
energy of the bottom binding mode be comparable to the top binding mode (Table 5).
The conclusion made by comparing the bottom binding modes for each G4 system leads
to the second difference: each 3’ site is different and as a result has a different effect on
CX-5461 binding, which we discuss in more detail further in the discussion. The third
major difference is the trend of the MSMs. As mentioned, the structural symmetry of the
human telomeric system clearly differentiated it from the c-KIT1 and c-Myc, but the two
non-symmetric G4s also had stark differences from each other. Most notably, the c-Myc
systems bottom binding pose was determined to be the most thermodynamically unstable
by the MM/PBSA binding energy analysis. This is demonstrated in the MSM where the
bottom binding mode is a lowly abundant state which we suggest likely acts as an off
pathway intermediate state. We believe this happens by CX-5461 binding to the bottom
of the G4 from an unbound state and once again goes back to the unbound state and
follows one of the other pathways which leads to the thermodynamically favorable top
binding mode. In contrast to the c-KIT1 G4 system which utilizes the bottom binding
mode as one of its on-pathway intermediates before leading to the more
thermodynamically favorable top binding mode. Together, understanding these
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similarities and differences allowed us to provide insight into the binding mode and
mechanism of CX-5461 and make sense of the experimental phenomenon published on
CX-5461’s affinity and selectivity to these targets.
Our simulation protocols and final binding poses were validated by comparing the
binding of CX-5461 to the c-Myc promoter G4 in our study to the only experimentally
solved structure of these G4s in complex with a small molecule to date. This was the
binding pose of Phen-DC3 in complex with Pu24T (PDB ID: 2MGN) which was solved
using NMR spectroscopy 190. Our study used Pu24T, the intramolecular G-quadruplex
formed from the c-Myc promoter, from the Phen-DC3-Pu24T complex and simulated this
G4s interactions with CX-5461. The major binding mode of CX-5461 identified in our
study closely matches the binding pose of Phen-DC3 solved using NMR spectroscopy
(Figure 24). The highly flexible 5’ terminal segment binds to and stabilizes both Phen-DC3
and CX-5461 into an intercalation to the top G-quartet where the 5’ terminal residue is
bound to the center aromatic core of both ligands. This comparison provides support that
the key interactions for this G4 are π-stacking with the guanine bases of the top G-tetrad,
as well as validation for the simulation methods used in our study. Our study also supports
the prediction made by Xu and coworkers117 which suggests that CX-5461 may also be an
end stacking G4 stabilizer due the structural relationship between CX-5461 and QQ58
(Figure B33), which was biophysically determined to be an end stacking G4 stabilizer in
one study.
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Figure 24. Major binding mode comparison of the CX-5461-Pu24T complex and PhenDC3-Pu24T Complex (PDB ID: 2MGN). 5’ and 3’ of the DNA chain are indicated by a
red and blue sphere, respectively. K+ cations are represented by yellow spheres.

As mentioned in the introduction, Xu and co-workers FRET-melting temperature
increase assay 117 was performed to determine the affinity of CX-5461 binding to the G4s
and duplex structure. A higher binding affinity was correlated to a higher melting
temperature increase which indicated more energy was required to break the bonds formed
upon CX-5461 binding, and was essentially a measurement of enthalpy. The results of their
assay indicated that with 10 µM CX-5461 the highest melting temperature increase, and
thus the stabilizing effect due to CX-5461 binding, was demonstrated by the human
telomeric system (~30 K) followed by the c-KIT1 G4 (~27 K), the c-Myc G4 (~25 K) and
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the DNA duplex (~10 K). Evident from this data, CX-5461 stabilizes the three G4 systems
much more than the DNA duplex (~15-20 K). But what was causing marginally different
melting temperature increases (~2-5 K) for the three G4 systems? In our study, each
system’s MM-PBSA binding energy calculations, which are also a measurement of binding
enthalpy, were consistent with the order of stabilizing effect upon CX-5461 binding
determined in the FRET-melting temperature assay (Table 5). CX-5461’s average
MM/PBSA over the major poses were calculated for the human telomeric (-28.6 kcal/mol),
c-KIT1 (-23.9 kcal/mol), c-Myc (-22.0 kcal/mol) G4s, and DNA duplex (-15.0 kcal/mol)
systems. Evident from this, the three G4 systems much higher MM-PBSA binding energies
as compared to the DNA duplex. Thus, it appears that the binding energy differences lead
to the observed difference in the melting temperature change for these systems.
The unique structural differences at the 3’ region provide insight into the binding
modes and the binding energy differences. Due to the structural symmetry of the human
telomeric G4, the binding poses and binding energies of the top (-37 kcal/mol) and bottom
(-33 kcal/mol) modes were very comparable. However, this was not true for the c-KIT1
and c-Myc G4s, which contain 3 (GGA) and 4 (GAAG) residue long diagonal loops,
respectively, on the 3’ end. Instead, the bottom binding mode of c-Myc had a very
unfavorable MMPBSA binding energy (-15.5 kcal/mol) which was comparable to the
duplex system (~-15 kcal/mol), and the c-KIT1 system was not much more favorable (-22
kcal/mol). In these systems we observed a decreased ability for CX-5461 to interact
directly with the third G-quartet due to hindrance from the diagonal loops which led to
unequal binding opportunities when compared to the top binding mode. From our analysis
we suggest that the more ordered diagonal loop of c-KIT1, which contains an A16-G20 base
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pair, may contribute to the marginally higher stability determined from the FRET-melting
temperature assay, when compared to the c-Myc G4 which contains the 4 residue diagonal
loop (GAAG). Although CX-5461 was not able to intercalate onto the 3’ G-quartet for the
c-KIT1 and c-Myc G4’s there was one case for both the c-KIT1 and c-Myc G4s where CX4561 was able to intercalate into the 3’ diagonal loop connecting the 3’ G-tetrad, but our
MMPBSA binding energy analysis revealed this binding mode was even less favorable in
both the c-KIT1 (-11.66 kcal/mol) and c-Myc (-13.17 kcal/mol) systems. These facts help
to explain why both of these G4s have a lower binding energy and melting temperature
increase than the human telomeric G4, but also why the c-KIT1 G4 has a marginally higher
affinity and binding energy when compared to the c-Myc G4. Thus, we propose that the
structural differences at the 3’ region of each G4 causes unequal CX-5461 binding
opportunities which made for differences in our observed binding modes and may also play
a critical role in the experimentally reported affinities from the melting temperature
increase assay.
Along with characterizing the binding features of CX-5461’s in each system to
understand CX-5461s major role as a G4 binder and stabilizer observed in experiments,
our study aimed to provide insight into the selectivity of CX-5461 to G4 structures over
DNA duplex. The motivation for this is based on the major finding from the FRET-melting
temperature assay performed by Xu and co-workers research showed CX-5461 selectively
binds to and stabilizes G4 structures over duplex DNA117. This is an extremely desirable
feature for a G4 stabilizer, since a major limiting factor for the therapeutic use of this class
of drugs is the lack of selectivity to G4s over DNA duplex structures. Encouragingly, our
trajectory analysis supports the selectivity of CX-5461 to G4s. The major finding used to
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conclude this was that for each of our G4 systems, an intercalation mode was observed for
CX-5461, however for our duplex DNA system no groove intercalation mode was
observed. The effects of this lack of highly stable binding pose in the duplex system was
supported by MMPBSA binding energy analysis which showed that the duplex system had
the lowest binding energy. The most energetically favorable binding pose observed in our
duplex DNA system (-15.0 kcal/mol) was only comparable to the least favorable binding
poses of the G4 systems, supporting that CX-5461 is selective to G4 structures over duplex
DNA. In addition, our simulation analysis which supports that CX-5461 is not a DNA
duplex intercalator is consistent with an intercalation assay comparing CX-5461’s ability
to intercalate into calf thymus DNA to a known DNA intercalator Actinomycin-D118. This
assay even showed that CX-5461 was even a weak minor groove binder at concentrations
as high as 50 µM, which is consistent with our less favorable binding energy calculations
for CX-5461 to the duplex when compared to the G4s.
To further compare the binding of CX-5461 to a known intercalator, we compared
the binding pose of CX-5461 to RHPS4, another G4 ligand with an aromatic core (Figure
B34) from our previous work.
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Evident from comparing the chemical structures, CX-

5461 is longer and contains two flexible side chains whereas RHPS4 maintains a very
planar aromatic structure. In the previous work, RHPS4 was modeled with the same duplex
DNA and human telomeric G4 structure (1KF1) used in this work, among other G4s.
RHPS4 was able to fully intercalate into the duplex DNA with a binding energy of 46.8±4.6 kcal/mol and in the human telomeric simulations the most favorable binding
mode was bottom stacking with a MMPBSA binding energy of -48.9±2.4 kcal/mol.
RHPS4’s lack of selectivity toward a DNA structure indicated modifications were needed
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for it to be a successful G4 stabilizer. In this study, CX-5461 demonstrates an advantage in
G4 selectivity over RHPS4 which we attribute to the two aromatic side chains of CX-5461.
These two side chains limit CX-5461’s planarity and therefore ability to fit into the narrow
grooves of the DNA duplex structure. From our observations we believe that the positive
charge on the methyl diazepane side chain, coupled with the flexibility of the
methylpyrazine side chain, contributes to the selectivity of CX-5461 to G4 structures over
duplex DNA.
Taking a deeper look at the overall binding pattern of CX-5461 to the DNA
duplex, since it was clear CX-5461 was not a DNA duplex intercalator, we observed
trajectories which showed an interesting mechanism comparable to a recent study.192 It is
conventional that a ligand may completely unbind and begin researching for a binding
site in cases where ligand binding is not favorable. In our duplex system however, in
cases when ligand binding was not favorable, we observed CX-5461 diffusing the surface
of the DNA duplex searching for a stable binding site, maintaining a partial interaction
throughout the entire binding process. This was made even clearer when the trajectory
was extended from 500 ns to 2000 ns and provides unique insight into the binding
interactions of CX-5461 to the duplex. We see that the drugs side chains (R1 and R2) are
able to maintain interactions with the DNA, however a favorable binding pose is not
achieved due to the lack of intercalation into the grooves of the duplex. Since the major
factor limiting the therapeutic use of DNA G4 stabilizers to date has been a lack of
selectivity to the DNA duplex, we kept this mechanism in mind when suggesting possible
optimizations to this drug.
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We developed a hypothesis to increase the binding of CX-5461 to the G4
structures and decrease the binding of CX-5461 to the duplex structure based on our
analysis of the detailed interactions of each binding mode at the G4 and duplex
structures. The detailed interactions (Figures B11-B13) of the most thermodynamically
favorable binding poses (Figures 14; Table 5) indicate that CX-5461’s rigid core (Figure
12) binding to the G4s is essential in stable binding. One level of support for this
conclusion is that the core of CX-5461 is not exposed to solvent in our two dimensional
interaction diagrams of the most thermodynamically favorable top binding poses (Figure
B12). Further, the second most thermodynamically favorable pose, human telomeric G4
bottom binding (Figure B11A), also shows that the rigid core shows very little exposure
to solvent. However in the c-KIT1 and c-Myc bottom mode and all three G4 systems
groove binding mode, the amount of solvent the rigid core of CX-5461 is exposed to is
far greater (Figure B11 A-D). With these facts in mind we were able to suggest minor
modifications be made to the benzothiazole-based scaffold of CX-5461 with the
hypothesis that increasing the length of the core could increase the binding energy and
stability. At each possible point of substitution, we picked 2 function groups (fluorine or
chlorine) that could be substituted for hydrogen (Figure 25; Figure B35) leaving a total
56 compounds generated in our combinatorial library. Each new compound was docked
to the same orthosteric binding site as the most abundant cluster for the most
thermodynamically favorable top binding mode, and showed similar hydrogen bonds, π-π
and hydrophobic interactions. Of these compounds, we chose four derivates (Figure 25)
based on their synthesizability as determined by a minimal number of functional groups
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added, and their more negative XP docking scores for the G4 but less negative XP
docking scores for the Duplex DNA.
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Chemical Structure of CX-5461: Substitution
Sites Marked
S3

Docking Score

S4

h-Tel: -8.386
CKIT1: -8.112
c-Myc: -8.567
Duplex: -5.944

S1
S2

Chemical Structure of New Ligand

Docking Score

△CX-5461

h-Tel: -8.930
CKIT1: -8.552
c-Myc: -9.165
Duplex: -4.241

h-Tel: -0.544
CKIT1: -0.440
c-Myc: -0.598
Duplex: +2.703

h-Tel: -9.272
CKIT1: -8.771
c-Myc: -8.818
Duplex: -3.326

h-Tel: -0.886
CKIT1: -0.659
c-Myc: -0.251
Duplex: +2.618

h-Tel: -8.913
CKIT1: -8.179
c-Myc: -8.808
Duplex: -4.334

h-Tel: -0.527
CKIT1: -0.067
c-Myc: -0.241
Duplex: +1.610

h-tel: -9.179
c-KIT1: -8.175
c-Myc: -8.667
Duplex: -5.273

h-Tel: -0.793
CKIT1: -0.063
c-Myc: -0.100
Duplex: +0.671

Figure 25. Chemical structure of CX-5461 and derivates identified through virtual
screening, including docking scores. For CX-5461 green arrows indicate substitution sites
for the derivates on this table. For the derivates, docking scores are provided as well as
the difference between their docking scores and CX-5461.
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While picking possible substitution sites, we closely compared our work to the
original structure activity relationship study for which CX-5461 was identified118. Of
note, their work found that the addition of a F at our position S3 significantly increased
the cellular activity of the compound, to a level even higher than reported for CX-5461.
However, this addition was not made to CX-5461 itself. Rather than using the
methylpyrazine based flexible side chain R2 (Figure 12) for their trial at this site they
used a pyrrolidinoethylamine side chain. They discovered that this combination, although
highly beneficial in terms of cellular activity, had an extremely low oral absorption. They
later discovered that the addition of the methylpyrazine based side chain (R2) drastically
increased the oral availability (~40-fold increase: ~2,300 to ~92,000 ng h/mL), however
failed to revisit the possibility of using F at substitution site S3 with the addition of R2 to
the aromatic core. Which led us to believe that because R2 provides such a drastic
increase in oral availability, and the F at site S3 leads to a drastic increase in cellular
activity, this combination could provide the resolve for both important factors. Our
docking results further supported the promise of this combination where F at site S3
increased the binding to all G4’s and provided the largest decrease in duplex binding
(+2.703 kcal/mol) of all our derivatives. A closely following second was a Cl substitution
at site S3 which also increased G4 binding and decreased duplex binding (+2.618
kcal/mol). A third ligand was identified which substituted F at site S3 and Cl at site S1
which increased G4 binding and decrease duplex binding (+1.610 kcal/mol). In addition
to these ligands, we identified a number of other derivates which could be promising.
This includes a ligand with F substitutions at sites S2 and S4 which increased binding for
each the human telomeric, c-KIT1 and c-Myc G4s and decreased duplex binding (Figure
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25) and a ligand which had a Cl substitution at site S2 which increased binding for each
the human telomeric and c-Myc G4s but decreased binding for both the c-KIT1 G4 and
duplex (Figure B35). All together suggesting substitutions at site S3 may address both
the necessary biological properties as well as well as the intended decrease in duplex
binding.
Furthermore, an interesting trend was observed for the human telomeric system.
First, of the 56 ligands the intended effect (i.e. increase G4 binding or decrease duplex
binding) was most observed for the human telomeric G4 system (48%) followed by the
duplex (44%). Looking closer at the docking results, there were many new derivatives
which produced the intended effect in just the human telomeric and duplex systems, six
of which are exemplified in the supporting document (Figure B35). Putting together the
most thermodynamically favorable system in our study was the human telomeric G4, the
stability results of the melting temperature assay, and the results of our docking study, we
suggest that using CX-5461 derivatives to specifically target the human telomeric G4
could be a promising therapeutic approach. This hypothesis is consistent with limited
experimental testing such as a telomere FISH assay117 which showed an increased
frequency of telomere defects in BRCA -/- HCT116 cells after exposure to CX-5461
which they used to provide support of CX-5461’s G4 stabilizing and ability to induce
genome instability specifically at G4s in human cells. However, only targeting human
telomeric G4 provides a limited solution that ties back into a major limiting factor of G4
stabilizers to date, whereby, the structure of the G4s overall do not provide a large
binding pocket, as seen in proteins and other targets. This has implications on the
reported efficacies where a G4 stabilizer has yet to bind in the nM concentration range.
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One approach to remedy this is to generate a hybrid G4 binder that has both the
pharmacophores of a G4 intercalator and groove binder. The intention of this ligand
design is that the intercalator core of this ligand will intercalate onto a G-quartet and, that
when connected by a flexible linker, the groove binder like side chains may wrap around
the G4 core like arms and further stabilize the interactions. As far as we know, there has
been no such ligand developed with this binding pose to date. Of course, further
experimentation is required to support this hypothesis.
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Appendix A
Binding of BRACO19 to a Telomeric G-Quadruplex DNA Probed by All-Atom
Molecular Dynamics Simulations with Explicit Solvent

DNA Duplex + Unbound BRACO19

3(-p-p-p) DNA G-Quadruplex + Unbound
BRACO19

3(-lwd+ln) DNA Quadruplex + Unbound
BRACO19

3(-p-lw-ln) DNA Quadruplex + Unbound
BRACO19

Figure A1. Initial structures of the simulation systems. 5’ and 3’ are indicated by a red and
blue ball, respectively.
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Figure A2. RMSD of the BRACO19-duplex DNA complex in each trajectory.
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Figure A3. The contact number between BRACO19 and the duplex DNA in each
trajectory.
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Figure A4. RMSD of the parallel topological fold of DNA in complex with BRACO19 in
each trajectory.
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Figure A5. The contact number between the parallel topological fold of DNA and
BRACO19 in each trajectory.

134

Figure A6. RMSD of the anti-parallel topological fold of DNA in complex with BRACO19
in each trajectory.
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Figure A7. The contact number between the anti-parallel topological fold of DNA and
BRACO19 in each trajectory.
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Figure A8. RMSD of the hybrid topological fold of DNA in complex with BRACO19 in
each trajectory.
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Figure A9. The contact number between the hybrid topological fold of DNA and
BRACO19 in each trajectory.
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Front View

Description

Front View

Description

Run 01 (Groove)

Run 06 (Groove)

Run 02 (Groove)

Run 07 (Groove)

Run 03 (Groove)

Run 08 (Top)

Run 04 (Bottom)

Run 09 (Groove)

Run 05 (Groove)

Run 10 (Groove)

Figure A10. Last snapshots of the 10 BRACO19-duplex DNA complex simulations. 5’ and
3’ arc indicated by a red and blue ball, respectively.
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Front View

Description

Front View

Description

Run 01 (Top)

Run 06 (Top)

Run 02 (Top)

Run 07 (Bottom)

Run 03 (Bottom)

Run 08 (Top)

Run 04 (Bottom)

Run 09 (Bottom)

Run 05 (Groove)

Run 10 (Groove)

Figure A11. Last snapshots of the 10 3(-p-p-p)-BRACO19 complex simulations. 5’ and 3’
arc indicated by a red and blue ball, respectively.
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Front View
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Figure A12. Last snapshots of the 10 3(-lwd+ln)-BRACO19 complex simulations. 5’ and
3’ arc indicated by a red and blue ball, respectively.
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Figure A13. Last snapshots of 10 hybrid BRACO19 complex simulations. 5’ and 3’ arc
indicated by a red and blue ball, respectively.
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Figure A14. Representative structures of the most populated complex structure families
(population ≥ 1 %) from the clustering analysis of the combined binding trajectories. 5’
and 3’ are indicated by a red and blue ball, respectively for the DNA duplex-BRACO19
complex system.
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Figure A15. Representative structures of the most populated complex structure families
(population ≥ 1 %) from the clustering analysis of the combined binding trajectories. 5’
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and 3’ are indicated by a red and blue ball, respectively for the 3(-p-p-p)-BRACO19
complex system.
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Figure A16. Representative structures of the most populated complex structure families
(population ≥ 1 %) from the clustering analysis of the combined binding trajectories. 5’
and 3’ are indicated by a red and blue ball, respectively for the 3(-lwd+ln)-BRACO19
complex system.
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Figure A17. Representative structures of the most populated complex structure families
(population ≥ 1 %) from the clustering analysis of the combined binding trajectories. 5’
and 3’ are indicated by a red and blue ball, respectively for the 3(-p-lw-ln)-BRACO19
complex system.
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(D) Top Stacking Mode of anti-parallel
G-Quadruplex

(C) Groove Binding Mode of 3(-p-p-p)
G-Quadruplex
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(F) Bottom Stacking Mode of antiparallel G-Quadruplex

(E) Groove Binding Mode of antiparallel G-Quadruplex
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(H) Groove Binding Mode of anti-parallel
G-Quadruplex

(G) Top Stacking mode of hybrid GQuadruplex

(I) Bottom Stacking Mode of hybrid GQuadruplex
Figure A18. 2D interactions of BRACO19 in representative structures of (A) Groove Binding
Mode of the Duplex DNA, (B) Top Stacking mode of the parallel G-Quadruplex, (C) Groove
Binding Mode of the parallel G-Quadruplex, (D) Top Stacking mode of the anti-parallel GQuadruplex, (E) Groove Binding Mode of the anti-parallel G-Quadruplex, (F) Bottom Stacking
Mode of the anti-parallel G-Quadruplex, (G) Top Stacking mode of the hybrid G-Quadruplex,
(H) Groove Binding Mode of the anti-parallel G-Quadruplex and (I) Bottom Stacking Mode of
the hybrid G-Quadruplex.
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Figure A19. Another representative groove binding trajectory of the duplex DNA. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue ball,
respectively. Bottom: An order parameter plot depicting number of hydrogen bonds present in
first base pair (green), second base pair (red) and third base pair (blue) tetrads of the DNA
structure (figure 2), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD
relative to the original crystal pose, center-to-center distance and MM-GBSA binding energy
(ΔE) (cf. methods section for definition).
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Figure A20. Another representative top stacking trajectory of the parallel G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue ball,
respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red
and the K+ ions are represented in yellow. Bottom: An order parameter plot depicting number of
hydrogen bonds present in first G4 (green), second G4 (red) and third G4 (blue) tetrads of the DNA
structure (Figure 2), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative
to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red) and
MM-GBSA binding energy (ΔE) (cf. methods section for definition).
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Figure A21. A representative bottom binding trajectory of the parallel G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue ball,
respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red
and the K+ ions are represented in yellow. Bottom: An order parameter plot depicting number of
hydrogen bonds present in first G4 (green), second G4 (red) and third G4 (blue) tetrads of the
DNA structure (Figure 2), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD
relative to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance
(R/red) and MM-GBSA binding energy (ΔE) (cf. methods section for definition).
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Figure A22. A representative top groove binding trajectory of the anti-parallel G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue ball,
respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red
and the K+ ions are represented in yellow. Bottom: An order parameter plot depicting number of
hydrogen bonds present in first (red), second G4 (cyan), third G4 (blue), fourth G4 (black) and
fifth (green) layers of the DNA structure (Figure S9), the drug-base dihedral angle, receptor (red)
and ligand (black) RMSD relative to the original crystal pose, center-to-center distance (R/black)
and K+-K+ distance (R/red) and MM-GBSA binding energy (ΔE) (cf. methods section for
definition).
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Figure A23. Another representative bottom stacking trajectory of the anti-parallel G-quadruplex.
Top: Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated
in red and the K+ ions are represented in yellow. Bottom: An order parameter plot depicting
number of hydrogen bonds present in first G4 (green), second G4 (red) and third G4 (blue)
tetrads of the DNA structure (Figure 2), the drug-base dihedral angle, receptor (red) and ligand
(black) RMSD relative to the original crystal pose, center-to-center distance (R/black) and K+-K+
distance (R/red) and MM-GBSA binding energy (ΔE) (cf. methods section for definition).
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Figure A24. Another representative top binding trajectory of the hybrid G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue ball,
respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red
and the K+ ions are represented in yellow. Bottom: An order parameter plot depicting number of
hydrogen bonds present in first G4 (green), second G4 (red) and third G4 (blue) tetrads of the DNA
structure (Figure 2), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative
to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red) and
MM-GBSA binding energy (ΔE) (cf. methods section for definition).
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Figure A25. Another representative bottom binding trajectory of the hybrid G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue ball,
respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red
and the K+ ions are represented in yellow. Bottom: An order parameter plot depicting number of
hydrogen bonds present in first G4 (green), second G4 (red) and third G4 (blue) tetrads of the
DNA structure (Figure 2), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD
relative to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance
(R/red) and MM-GBSA binding energy (ΔE) (cf. methods section for definition).
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Figure A26. Another representative groove binding trajectory of the hybrid G-quadruplex. Top:
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue ball,
respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red
and the K+ ions are represented in yellow. Bottom: An order parameter plot depicting number of
hydrogen bonds present in first G4 (green), second G4 (red) and third G4 (blue) tetrads of the
DNA structure (Figure 2), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD
relative to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance
(R/red) and MM-GBSA binding energy (ΔE) (cf. methods section for definition).
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Figure A27. Backbone Torsion Angles of DNA.
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Figure A28. Comparison of Tel26 hybrid G-quadruplex-Pt Tripod Complex Crystal
Structure (PDB ID: 5Z80) to Tel26 hybrid G-quadruplex-BRACO19 Complex. The 5’
residues are represented by a red ball and the 3’ residues in blue.
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Figure A29. Representative snapshots of BRACO19 using groove binding as an
intermediate state in each DNA G-quadruplex system: parallel (A), anti-parallel (B), and
hybrid (C). The snapshots that BRACO19 is in a groove binding mode are in red. The 5’
residues are represented by a red ball and the 3’ residues in blue.
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Figure A30. BRACO19 binding to the G-quadruplexes using an induced fit binding
mechanism. The 5’ residues are represented by a red ball and the 3’ residues in blue.

171

C

B

D

Top View

Side View

A

Figure A31. Sampling plot of BRACO19 in complex with the (A) Parallel (B) AntiParallel (C) Hybrid and (D) DNA duplex systems.
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Appendix B
To Probe the Binding of CX-5461, an Anti-Cancer DNA G-Quadruplex Stabilizer,
to Human Telomeric, c-KIT-1, and c-Myc G-Quadruplexes and a DNA Duplex
Using Molecular Dynamics Binding Simulations

Supporting Experimental Methods
Stability of Simulation Systems. The root mean square deviation (RMSD) of the DNA
backbone for each apo form was calculated against the initial structure (Figure 2) and
stability of the DNA structures was indicated by the flat and small RMSDs in all runs
(Figure S1). Last snap shots of the DNA only systems (Figures S2), and representative
trajectories including order parameter plots (Figure S3) are provided in the supporting
document.
Convergence of simulations. A plot showing the position of CX-5461, represented by one
atom, in each trajectory is presented (Figure S4) and indicates good sampling in each
system. The root mean square deviation (RMSD) of the DNA backbone was calculated
against the initial structure for the complex systems and the stability of the DNA structures
was indicated by the flat and small RMSDs in all runs (Figure S5). Atom contacts between
the DNA structure and the ligand were calculated using a 3.0 Å cutoff (Figure S6). The
stable contact number indicates the simulation systems reached a steady state in all runs
where a stable complex was defined as a complex with a number of atom contacts between
the DNA and ligand greater than 30. Last snap shots of the complex systems are provided
in the support document (Figures S7-S10).
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G-quadruplex and DNA Duplex Parameters. Following the methods from our previous
study186 the rise, helical rise (H-rise), and helical twist (H-twist) were calculated to gain
insight on the inter G4 layer geometry (Table S2). Using the Curves+193 program, we
calculated 20 helical parameters to characterize the base pairing of the DNA duplex in
regard to the base pair axis (Table S3), intra-base pairs (Table S4), inter-base pairs (Table
S5), as well as the puckering conformations of each residue (Table S6).
Featurization and Clustering. For each of the four systems, 30 trajectories (501 ns
each) were combined into one trajectory. Using VMD, all frames in which there were less
than 13 interactions, at a distance less than 3Å, between the G-quadruplex and the ligand
were separated as the unbound state 194 for the G-quadruplex systems. The trajectory was
then superimposed based on the nucleic backbone using MDtraj and calculations for
RMSD as well as center of mass of the ligand heavy atoms were performed 195. K-means
clustering, performed using scikit-learn, was then used to classify the remaining frames
into various states 196. Clustering was performed for K between 2 and 30 inclusively,
using the silhouette index as the metric for similarity of clusters 196, 197.
The most representative frame for each cluster was determined by calculating the
mean RMSD for each cluster and finding the frame with the least difference from the mean.
Further validation of the clustering was performed by creating a trajectory for each of the
clusters containing all of the frames in each cluster and visually confirming the similarity
within each cluster. Through visual analysis of the cluster representative frames, clusters
that were determined to be highly similar were combined. The unbound frames were then
reintroduced as a single cluster. Statistics of the clustering analysis are provided in the
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supporting document (Table S1). The number of each unique binding pathway’s taken for
each system is summarized in Table S2. Each structural family identified for the duplex
system is reported in Figure S11.
Transition Path Theory. Count matrices were then created for lagtimes (τ) of 1, 10, 20,
30 … 500 ns by counting the number of observed transitions between discrete states such
that the count of transitions from state i to state j (cij) is the sum of the number of times
each of the trajectories were observed in state i at time t and in state j at time 𝑡 + 𝜏, for
all 𝑡 ≤ 𝑡𝑚𝑎𝑥 − 𝜏 198. The count matrices were symmetrized (symij) such that 𝑠𝑦𝑚𝑖𝑗 =
𝑠𝑦𝑚𝑗𝑖 =

𝑐𝑖𝑗 +𝑐𝑗𝑖
2

and then row-normalized (normij) such that 𝑛𝑜𝑟𝑚𝑖𝑗 =

𝑠𝑦𝑚𝑖𝑗
𝑗=𝑛

∑𝑗=1 𝑠𝑦𝑚𝑖𝑗

. For the

purpose of determining the lag time at which the model has converged, the implied
timescale of each cluster was calculated for all lag times and plotted (Figure S12). The
implied timescale of the first cluster is not included in the plot as the eigenvalue is always
1 and thus contributes no information199. The 1KF1 system nodes are labelled 2 for top
binding, 3 for side binding, and 4 for bottom binding. The 2MGN system nodes are
labelled 2 for top binding, 3 for bottom binding, and 4 for side binding. The 4WO3
system nodes are labelled 2 for side binding, 3 for bottom binding, and 4 for top binding.
Further validation that the model had been converged was performed through the
Chapman-Kolmogorov test (Figure S13)198. Network models (Figure S14) were then
generated based on the count matrices at optimal lag times of 150, 100, and 170 ns for the
1KF1, 2MGN, and 4WO3 systems respectively with the cutoff for a directed edge in the
network being set at 50 transitions200. Edges in the network diagram are drawn if there
were at least 50 transitions (in any single direction) between two nodes. Outgoing
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transitions are labelled on the edges as the same color as the originating node. The 1KF1
system nodes are labelled 1 for unbound, 2 for top binding, 3 for side binding, and 4 for
bottom binding. The 2MGN system nodes are labelled 1 for unbound, 2 for top binding, 3
for bottom binding, and 4 for side binding. The 4WO3 system nodes are labelled 1 for
unbound, 2 for side binding, 3 for bottom binding, and 4 for top binding. Thereafter, the
mean first passage times (Fif ) at the optimal lag times and the standard deviations from
the optimal lag times to 300 ns were calculated according to the formula 𝐹𝑖𝑓 = 𝜏 +
∑𝑗≠𝑓 𝑃𝑖𝑗 𝐹𝑗𝑓 , with the boundary condition 𝐹𝑓𝑓 = 0, where τ is the lag time used to
construct the transition matrix P(τ). Summary plots were generated showing the The
mean first passage times between the four states (unbound, side transition, top, and
bottom) of the CX-5461 and human telomeric (Figure 4), c-KIT1 (Figure 5), and c-Myc
(Figure 6) DNA G-quadruplex complex systems.
Order parameters characterize the DNA-drug binding pathway. The DNA-drug
binding process was characterized using seven order parameter calculations: hydrogen
bond analysis, drug-base dihedral angle, drug center to ligand center distance (R), K+-K+
cation distance, DNA and ligand RMSD and MM-GBSA binding energy (ΔE) (Figures 715;Figures S15-S25). The distance cutoff between H-donor and H-acceptor was set to be
3.5Å and the donor-H-acceptor angle cutoff was set to be 120°. The hydrogen bonds were
calculated for the top/first, middle/second and bottom/third base layers, and other base
pairing when applicable (Figure 2 E-H). A visual representation of the hydrogen bond
networks are presented in the supporting document (Figures S29-S31). The definition for
the quadruplexes is the three guanine layers with the 5’ side as the first layer. The center176

to-center distance (R) was defined in two ways: as the length from the DNA center to the
drug molecule center and the length between the two K+ cations within the G-quadruplex
structure. The dihedral angle was defined as the dihedral angle between the plane of the
stable unbroken base-layer of the DNA that is closest to the drug binding site and the drug’s
ring plane. MM-PBSA201 (Molecular Mechanics Poisson Boltzmann Surface Area) module
in the AMBER package (PB1 model with mBondi radii set, salt concentration of 0.2 M,
and surface tension of 0.0378 kcal/Å2) was used to analyze the energetics of the bound
complexes. The MM-PBSA binding energy for a system was calculated based on three
simulations: the ligand only, the DNA only and the DNA-ligand complex using equation
1. The equation is made of four components Eq2: van der Waals interaction energy (VDW),
hydrophobic interaction energy (SUR), electrostatic interaction (GBELE) and the change
of the conformation energy for DNA and ligand which are calculated using equation 3 and
4.

MM-PBSA binding energy is an effective tool for ranking ligand binding affinities

proven by up to 1864 crystal complexes tested in systematic benchmarking studies. 202-206
Eq 1:

∆𝐸 = 𝐸𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝐷𝑁𝐴_𝑓𝑟𝑒𝑒 − 𝐸𝑙𝑖𝑔_𝑓𝑟𝑒𝑒

Eq 2:

∆𝐸 = ∆𝐸𝑣𝑑𝑤 + ∆𝐸𝑆𝑈𝑅 + ∆𝐸𝐺𝐵𝐸𝐿𝐸 + ∆𝐸𝑐𝑜𝑚𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛

Eq 3:

∆𝐸𝑥 = 𝐸𝑥𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑥𝐷𝑁𝐴

𝑐𝑜𝑚𝑝𝑙𝑒𝑥

− 𝐸𝑥𝑙𝑖𝑔

𝑐𝑜𝑚𝑝𝑙𝑒𝑥

,

x= vdw, sur and gbele
Eq 4:

∆𝐸𝐶𝑜𝑚𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 = 𝐸𝐷𝑁𝐴_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 +𝐸𝑙𝑖𝑔_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝐷𝑁𝐴_𝑓𝑟𝑒𝑒 − 𝐸𝑙𝑖𝑔_𝑓𝑟𝑒𝑒
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Structural fluctuation of the DNA. For each major binding mode and apo form
systems, the root mean square fluctuations (RMSF) of each individual residue of DNA
were calculated to characterize the local structural fluctuation (Figure S35).
Virtual Screening. The top derivative was chosen from a virtual screening of a CX-5461
derivate library using Maestro 10.3207. First, a combinatorial library of 64 ligands
prepared using the Interactive Enumeration program. The variants were defined by
establishing substitution sites where there were three possible points of substitution to
CX-5461. At each possible point of substitution there were 4 functional groups that can
be substituted which included hydrogen, fluorine, chlorine, bromine. This suggests that
there are 43 possible modified versions of CX-5461, and a combinatorial library of these
64 ligands was generated. The charge of each compound at pH=7 was determined by
Epik (an empirical pKa prediction program)208 followed by a geometry optimization that
minimized the potential energy using the default parameters. Using the active receptor
structure from the most abundant conformation of each system, a grid file was generated
using the Receptor Grid Generation program to prepare the complex for the subsequent
docking calculation. In each system, ergotamine or dihydroergotamine was selected and a
grid box was generated around the ligand with a van der Waals radius scaling factor of
1.0 and a partial cutoff of 0.25. Then, these 64 compounds were docked using Glide with
Extra Precision (XP) scoring function, and then filtered using QikProp package209, to
predict the absorption, distribution, metabolism, and excretion (ADME) properties.
QikProp ranks the full molecular structure based on pharmaceutically relevant properties
by giving each compound a number of stars; compounds with no starts are predicted to be
178

the most drug-like. Finally, three potential compounds for each ligands were manually
chosen based on XP scores (< -9.0 kcal/mol) that were more negative than the docking of
ERG or DHE into the active conformation of 5HT1B from the most abundant clusters,
along with the compounds’ synthesizability containing fewer substitution groups.
Table B1
Final binding mode statistics of the 30 simulation runs. Reported are the number of
trajectories in each system that intercalates to the top, stacks to the top or bottom, or
binds to a side residue in each of the simulation runs.
System
h-Tel
c-KIT1
c-Myc
Duplex

Top
Intercalation
10
7
17
1

Top Stacking
3
11
2
12
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Bottom
Stacking
7
6
3
10

Side Binding
10
7
8
7

Table B2
DNA G-quadruplex G4 layer geometry parameters for the apo form and two major binding
modes of the human telomeric (1KF1), c-KIT1 (4WO3) and c-Myc (2MGN) Gquadruplexes. 1-3: top layer, middle and G4 bottom, respectively.
Rise1

Parameter
Layers3

3:2

H-Rise1
2:1

3:2

H-Twist2
2:1

3:2

2:1

1KF1A

3.56±0.01 3.42±0.01 1.91±0.41 1.86±0.32

12.76±2.55

11.86±1.63

1KF1T

3.55±0.02 3.47±0.02 3.05±0.03 2.94±0.05

22.74±0.15

21.35±1.38

1KF1B

3.51±0.02 3.42±0.03 2.14±0.05 2.07±0.04

13.07±0.56

15.68±3.52

4WO3A

3.49±0.01 3.41±0.01 1.96±0.08 2.05±0.04

17.19±0.01

17.39±0.73

4WO3T

3.49±0.01 3.42±0.01 1.35±0.04 1.48±0.02

16.54±0.17

6.43±0.66

4WO3B

3.50±0.01 3.43±0.00 2.63±0.02 2.69±0.04

23.11 ±0.15

17.18±0.54

2MGNA

3.48±0.01 3.42±0.01 0.32±3.66 0.29±0.08

36.21±3.66

3.90±0.85

2MGNT

3.48±0.02 3.44±0.04 0.87±0.08 0.79±0.05

9.79±1.18

4.67±0.80

2MGNB

3.47±0.00 3.42±0.01 3.17±0.02 3.11±0.02

81.90±0.43

24.29±0.28

1

Values reported in Å
Values reported in degree
3
System legend: Apo (A), Top (T), Bottom (B)
2
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Table B3
Base pair axis parameters for the DNA duplex, abnormal values are in red.
BaseYA/ X-displacepair
DisplaceInclination3
Tip3
1
1
G
ment
ment2
1) G1-0.05±1.44
0.01±0.57
4.66±5.03
2.30±6.77
A
C20
G
-0.47±1.15
-0.45±1.04
13.21±41.43 -15.35±37.05
2) C2-0.47±1.24
-0.13±0.56
4.12±5.38
-0.46±6.05
A
G19
G
-0.55±0.77
-0.253±0.81
5.58±16.11
-1.65±8.88
3) G3-0.27±1.16
-0.04±0.63
7.71±6.59
5.94±4.02
A
C19
G
-0.57±0.82
0.14±0.78
6.01±7.94
1.28±7.74
4) C4-0.15±0.91
0.01±0.64
7.02±4.83
-1.00±5.15
A
G17
G
-0.75±0.87
0.09±0.67
7.99±6.97
-2.26±7.72
5) G5-0.33±0.85
0.31±0.43
5.77±6.68
1.41±2.63
A
C16
G
-0.60±0.92
0.52±0.35
6.96±3.51
0.53±6.78
6) C6-0.12±0.62
-0.14±0.77
4.50±6.60
-0.94±4.34
A
G15
G
-0.29±1.08
0.16±0.42
6.88±6.62
-3.88±4.44
7) G7-0.46±0.65
-0.02±0.79
6.82±4.62
2.42±4.78
A
C14
G
-0.09±1.12
0.29±0.65
5.05±3.84
1.57±3.79
8) C8-0.50±0.87
0.00±0.89
6.54±6.93
-6.18±3.33
A
G13
G
-0.06±0.85
-0.00±0.56
3.73±9.45
-5.60±2.15
9) G9-0.14±0.90
-0.01±0.73
4.54±6.46
-0.56±4.18
A
C12
G
0.48±1.18
0.01±0.67
0.13±13.15
-1.58±8.15
10)
C10A
-0.07±1.33
-0.32±0.78
5.83±7.31
-1.65±7.58
G11
G
0.25±1.56
-0.29±1.15
-6.04±26.73
-9.27±18.46
1
Apo (A) or Groove (G)
2
Values reported in Å
3
Values reported in degree
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Axis-bend3
----1.30±0.88
3.33±2.79
1.49±0.94
2.73±1.89
1.52±1.04
2.32±1.45
1.72±1.15
2.53±1.07
2.37±1.18
3.25±0.97
2.13±0.95
2.26±1.50
1.89±0.90
2.19±2.00
1.78±0.85
2.14±2.30
1.87±0.68
2.36±2.89

Table B4
Base pair step parameters, abnormal values are in red.
BaseA/
Shear2
Stretch2
Stagger2
pair
G1
1) G1C20
A
0.00±0.33
0.06±0.13 0.06±0.45
G -0.60±1.52 -1.34±3.14 0.06±3.32
2) C2G19
A
0.03±0.20
0.04±0.08 0.08±0.39
-0.05±0.24
0.06±0.10 0.17±0.33
G
3) G3C19
A -0.12±0.29 0.00±0.13 0.04±0.43
G -0.15±0.25 -0.01±0.11 0.30±0.26
4) C4G17
A -0.16±0.26 0.04±0.08 0.28±0.25
0.04±0.34
0.04±0.11 0.02±0.46
G
5) G5C16
A -0.09±0.27 0.05±0.10 0.16±0.37
G -0.03±0.14 0.00±0.07 0.19±0.16
6) C6G15
A -0.18±0.20 0.00±0.08 0.45±0.44
G -0.10±0.29 0.08±0.11 0.24±0.39
7) G7C14
A
0.09±0.32
0.03±0.09 0.22±0.32
G -0.04±0.19 0.04±0.11 0.28±0.42
8) C8G13
A -0.04±0.28 -0.04±0.13 0.00±0.47
0.04±0.39
0.04±0.10 0.18±0.46
G
9) G9C12
A -0.06±0.37 0.06±0.13 0.23±0.36
G -0.37±0.84 0.09±0.13 0.20±0.57
10)C10G11
A
0.19±0.38 -0.03±0.15 0.12±0.51
G -0.34±0.99 -0.82±2.63 1.41±4.93
1
Apo (A) or Groove (G)
2
Values reported in Å
3
Values reported in degree
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Buckle3

Propel3

Opening3

-0.02±13.44
7.06±58.97

-0.64±6.01
-35.04±80.92

2.00±4.40
3.38±17.9

5.25±10.70
1.72±9.37

-10.37±10.54
-7.10±10.85

0.08±2.78
1.64±3.24

-4.97±7.96
6.32±9.18

-12.88±8.31
-3.81±8.62

1.74±3.32
1.49±3.77

-2.85±8.39
5.97±11.97

-10.53±10.67
-9.31±5.15

1.65±3.36
1.42±3.41

-2.97±10.13
-4.88±6.75

-5.82±10.97
-12.92±9.55

2.33±3.34
2.28±2.75

-4.37±11.10
-2.08±9.95

-12.46±7.58
-12.39±6.90

0.11±2.85
2.47±2.59

-1.71±7.21
-1.52±11.75

-8.86±8.23
-7.63±4.50

-0.48±3.69
-0.32±3.54

-1.74±10.17
1.51±9.38

-9.98±5.48
-10.82±5.98

0.29±2.29
-0.32±3.7

2.23±13.20
4.22±14.62

-6.04±6.27
-7.37±15.66

0.43±4.67
2.52±11.9

6.65±12.42
-5.81±23.54

-2.87±8.99
-11.59±46.49

0.42±2.84
6.60±17.1

Table B5
Paired base- base parameter, abnormal values are in red.
Pair
A/G1
Roll3
Twist3

H-Ris2

H-Twi3

G1/C2

A
G

-0.59±4.98
18.97±57.09

31.51±6.47
22.85±17.69

3.25±0.25
3.59±2.20

31.78±6.31
33.99±23.19

C2/G3

A
G

9.67±6.61
6.45±6.23

38.35±6.86
33.72±7.08

3.43±0.35
3.09±0.38

38.93±6.50
34.15±7.67

G3/C4

A
G

-1.65±6.55
0.64±4.73

34.38±4.68
33.65±5.83

3.22±0.28
3.32±0.28

34.55±4.46
33.92±5.57

C4/G5

A
G

6.64±6.60
8.42±4.81

35.65±8.55
38.71±6.08

3.37±0.33
3.49±0.16

36.23±8.01
39.39±5.86

G5/C6

A
G

1.40±4.55
0.61±6.51

35.23±3.44
30.48±5.36

3.29±0.37
3.15±0.22

35.46±3.31
30.74±5.16

C6/G7

A
G

6.61±8.28
10.49±5.12

35.82±8.16
36.51±6.01

3.21±0.30
3.22±0.39

36.47±7.60
37.18±6.03

G7/C8

A
G

-3.90±6.56
-2.96±5.24

36.13±4.92
32.37±4.88

3.33±0.20
3.27±0.23

36.24±4.85
32.42±4.97

C8/G9

A
G

8.43±4.40
5.59±12.22

31.86±7.49
36.80±8.78

3.17±0.33
3.37±0.43

32.39±7.47
37.80±8.11

A
1.62±7.80
G
-6.56±13.84
1
Apo (A) or Groove (G)
2
Values reported in Å
3
Values reported in degree

33.71±5.61
30.36±12.23

3.30±0.29
3.49±0.41

34.25±5.36
31.85±8.53

G9/C10
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Table B5 (continued).
Pair

A/G1

Shift2

Slide2

Rise2

Tilt3

G1/C2

A
G

-0.41±0.63
0.84±2.64

0.15±0.45
0.30±2.00

3.30±0.31
2.73±2.00

-0.76±3.71
-1.68±34.15

C2/G3

A
G

0.26±1.05
0.38±0.86

0.15±0.84
0.28±0.51

3.47±0.30
3.15±0.29

0.88±7.36
0.01±5.48

G3/C4

A
G

-0.03±0.74
-0.09±0.58

0.24±0.69
-0.33±0.25

3.27±0.29
3.41±0.27

-2.53±4.23
1.87±4.13

C4/G5

A
G

-0.30±0.99
-0.14±1.05

0.46±0.71
0.02±0.51

3.39±0.30
3.48±0.17

-1.49±5.67
-1.26±6.45

G5/C6

A
G

0.09±0.42
-0.22±0.61

-0.40±0.39
-0.48±0.66

3.35±0.32
3.26±0.25

-1.11±3.11
-0.27±4.77

C6/G7

A
G

-0.37±0.95
-0.30±1.23

0.27±0.64
0.38±0.58

3.22±0.31
3.22±0.32

1.80±5.10
-0.97±7.33

G7/C8

A
G

0.11±0.59
-0.21±0.97

0.14±0.57
0.12±0.44

3.38±0.24
3.30±0.23

1.21±3.70
0.76±7.17

C8/G9

A
G

0.48±0.89
0.60±1.33

0.11±0.54
0.45±0.55

3.17±0.34
3.24±0.38

0.20±5.38
0.08±6.33

A
0.21±0.73
G
0.41±0.94
1
Apo (A) or Groove (G)
2
Values reported in Å
3
Values reported in degree

0.08±0.65
-0.22±0.67

3.33±0.33
4.18±2.27

1.80±3.64
-3.35±11.72

G9/C10
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Table B6
Percentage of each sugar pucker conformation.1
Pucker

C1'ex

Residue
G1
C2
G3
C4
G5
C6
G7
C8
G9
C10
C20
G19
C18
G17
C16
G15
C14
G13
C12
G11

C2'en

C3'ex

C3'en

C4'ex

O1'en

Apo Groove Apo Groove Apo Groove Apo Groove Apo Groove Apo Groove
50% 40% 40% 50% 10%
0%
0%
0%
0%
10%
0%
0%
50% 60% 50% 40%
0%
0%
0%
0%
0%
0%
0%
0%
40% 20% 10% 60% 40% 10%
0%
0%
10%
0%
0%
10%
40% 30% 50% 60% 10%
0%
0%
0%
0%
0%
0%
10%
30% 10% 60% 40% 10% 30%
0%
10%
0%
10%
0%
0%
20% 40% 60% 20%
0%
0%
0%
20% 10% 10% 10% 10%
30% 40% 40% 20% 30% 40%
0%
0%
0%
0%
0%
0%
40% 30% 50% 50%
0%
0%
0%
0%
10% 10%
0%
10%
30% 30% 40% 50% 10% 10%
0%
0%
10% 10% 10%
0%
40% 20% 40% 30% 10%
0%
0%
0%
10% 30%
0%
20%
70% 20% 20% 60%
0%
0%
0%
0%
0%
10% 10% 10%
30% 50% 50% 20% 20% 30%
0%
0%
0%
0%
0%
0%
30% 40% 60% 40%
0%
10%
0%
0%
0%
0%
10% 10%
40% 30% 20% 40% 30% 30%
0%
0%
0%
0%
10%
0%
30% 30% 20% 40% 40%
0%
0%
0%
0%
20% 10% 10%
60% 20% 30% 70%
0%
10%
0%
0%
0%
0%
10%
0%
0%
20% 90% 60%
0%
0%
0%
0%
0%
10% 10% 10%
10% 10% 60% 60% 30% 30%
0%
0%
0%
0%
0%
0%
20% 50% 50% 50% 10%
0%
0%
0%
0%
0%
20%
0%
30% 50% 60% 30% 10% 10%
0%
10%
0%
0%
10%
0%
1

Visual representation of the pucker conformations reported in Table B6.

210.

Ho, P.; Carter, M., DNA Structure: Alphabet Soup for the Cellular Soul. 2011.
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Table B7
Overall binding pathway taken by CX-5461 in each system for each of the 30 runs.
Binding Pathway

h-Tel

c-KIT1

c-Myc

Duplex

Top Intercalation

-

-

-

-

Top Stacking

-

2

1

10

4

-

1

-

-

1

11

-

-

1

-

-

-

1

-

-

Bottom Stacking

6

5

2

8

Bottom Stacking
to Bottom
Intercalation

-

-

1

-

Side Binding

7

4

5

6

3

2

3

1

7

3

4

1

-

7

2

1

-

3

-

-

2

1

-

-

1

-

-

3

Top Stacking to
Top Intercalation
5’ Terminal to
Top Intercalation
5’ Terminal to
Top Stacking
Bottom
Intercalation

Side Binding to
Side Binding
(reposition)
Side to Top
Intercalation
Side to Top
Stacking
Side to Top
Stacking to Top
Intercalation
Side to Top
Intercalation to
Top Stacking
Side Binding to
Bottom Stacking
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Figure B1. The average RMSD’s of the CX-5461 only runs, and the human telomeric Gquadruplex (1KF1), c-KIT1 G-quadruplex (4WO3), c-Myc G-quadruplex (2MGN), and
duplex DNA only runs.
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Figure B2. Last snap shots of the receptor only simulation runs.
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D
N

0 ns

479 ns

1342 ns

2000 ns

Figure B3. A representative trajectory of the human telomeric(A), c-KIT1(B), c-Myc(C),
and duplex(D) DNA only simulations, and the order parameter plot illustrating the
RMSD (Å) with reference to the final structure, K+ to K+ distance, and the MM-GBSA
binding energy(ΔE in kcal/mol). 5’ and 3’ of the DNA chain are indicated by a red and
blue ball, respectively. K+ ions are indicated by a yellow ball.
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Figure B4. Position plot of CX-5461 in each of the 30 trajectories for the (A) human
telomeric complex, (B) c-KIT1 complex, (C) c-Myc complex and (D) DNA duplex
systems
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Figure B5. The average RMSD’s of the human telomeric/CX-5641, c-KIT1/CX-5641, cMyc/CX5461, and duplex/CX-5461 complex systems in all runs.
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Figure B6. The average contact number between CX-5461 and the human telomeric Gquadruplex, c-KIT1 G-quadruplex, c-Myc G-Quadruplex, and DNA duplex in all runs.

193

Front View

Top/Bottom View
Run 01

Front View

Top/Bottom View
Run 06

Run 02

Run 07

Run 03

Run 08

Run 04

Run 09

Run 05

Run 10

194

Front View

Top/Bottom View
Run 11

Front View

Top/Bottom View
Run 16

Run 12

Run 17

Run 13

Run 18

Run 14

Run 19

Run 15

Run 20

195

Front View

Top/Bottom View
Run 21

Front View

Top/Bottom View
Run 26

Run 22

Run 27

Run 23

Run 28

Run 24

Run 29

Run 25

Run 30

Figure B7. The last snap shots of CX-5461 binding to the human telomeric DNA GQuadruplex in binding simulations 1-30.
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Figure B8. The last snap shots of CX-5461 binding to the c-KIT1 DNA G-Quadruplex in
binding simulations 1-30.
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Figure B9. The last snap shots of CX-5461 binding to the c-Myc DNA G-Quadruplex in
binding simulations 1-30.
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Figure B10. The last snap shots of CX-5461 binding to the Duplex DNA in binding
simulations 1-30.
205

2D Interactions

3D Side View

Groove Mode

Bottom Mode

Top Mode

A

206

3D Top View

2D Interactions

3D Side View

Groove Mode

Bottom Mode

Top Mode

B

207

3D Top View

2D Interactions

3D Side View

Groove Mode

Bottom Mode

Top Mode

C

208

3D Top View

2D Interactions

3D Side View

3D Top View

Groove Mode

Bottom Mode

Top Mode

D

Figure B11. Two dimensional interaction diagrams and three dimensional snapshots from
the side and top view showing key interacting residues of the human telomeric (A), cKIT1 (B), c-Myc (C) and Duplex (D) systems interacting with CX-5461 for the top,
bottom and groove binding modes.
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Figure B12. Comparison of the two dimensional interaction diagrams and three
dimensional snapshots from the side and top views of the human telomeric, c-KIT1, cMyc systems interacting with CX-5461 for the top binding mode.
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Figure B13. Comparison of the two dimensional interaction diagrams and three
dimensional snapshots from the side and top views of the human telomeric, c-KIT1, cMyc, and duplex systems interacting with CX-5461 for the groove binding mode.
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Figure B14. The mean first passage times between the four states (unbound, groove
binding, and top and bottom terminal binding) of the DNA duplex and CX-5461 complex
system.
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Figure B15. The implied timescale of each cluster for all lag times in the human
telomeric (A), c-KIT1 (B), c-MYC (C), and duplex (D) complex systems.
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Figure B16. Chapman-Kolmogorov test of the human telomeric (A), c-KIT1 (B), c-MYC
(C), and duplex (D) complex systems.
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Figure B17. Network Models of the human telomeric (A), c-KIT1 (B), c-MYC (C), and
duplex (D) complex systems.
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Figure B18. Snapshots from the representative trajectory of the bottom binding mode of
the human telomeric G4, run 26, including an order parameter plot. Illustrated in the plot
is the breaking and reforming of hydrogen bonds per layer (Top/Red, Middle/Green and
Bottom/Blue), drug-base dihedral angle, ligand(black)/DNA(red) RMSD (Å) with
reference to the final structure, ligand center to DNA center distance(black) and K+ to
K+ distance(red), and the MM-GBSA binding energy (ΔE in kcal/mol) . 5’ and 3’ of the
DNA chain are indicated by a red and blue ball, respectively. K+ ions are indicated by
yellow balls.
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Figure B19. Snapshots from the representative trajectory of the top binding mode of
4WO3, run 20, including an order parameter plot. Illustrated in the plot is the breaking
and reforming of hydrogen bonds per layer (5’ Face/Red, Top G-Tetrad/Cyan, Middle GTetrad /Blue, Bottom G-Tetrad /Black, and 3’ Face/Green), drug-base dihedral angle,
ligand(black)/DNA(red) RMSD (Å) with reference to the final structure, ligand center to
DNA center distance(black) and K+ to K+ distance(red), and the MM-GBSA binding
energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and blue ball,
respectively. K+ ions are indicated by yellow balls.
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1995 ns: Bottom of G4

Figure B20. Snapshots from the representative trajectory of the bottom binding mode to
the c-KIT1 G4, run 23, including an order parameter plot. Illustrated in the plot is the
breaking and reforming of hydrogen bonds per layer (5’ Face/Red, Top G-Tetrad/Cyan,
Middle G-Tetrad /Blue, Bottom G-Tetrad /Black, and 3’ Face/Green), drug-base dihedral
angle, ligand(black)/DNA(red) RMSD (Å) with reference to the final structure, ligand
center to DNA center distance(black) and K+ to K+ distance(red), and the MM-GBSA
binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and
blue ball, respectively. K+ ions are indicated by yellow balls.
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Figure B21. Snapshots from the representative trajectory of the bottom binding mode of c-KIT1 G4, run 24,
including an order parameter plot. Illustrated in the plot is the breaking and reforming of hydrogen bonds
per layer (5’ Face/Red, Top G-Tetrad/Cyan, Middle G-Tetrad /Blue, Bottom G-Tetrad /Black, and 3’
Face/Green), drug-base dihedral angle, ligand(black)/DNA(red) RMSD (Å) with reference to the final
structure, ligand center to DNA center distance(black) and K+ to K+ distance(red), and the MM-GBSA
binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and blue ball,
respectively. K+ ions are indicated by yellow balls.
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Figure B22. Snapshots from the representative trajectory of the side binding intermediate mode of c-KIT1
G4, run 19, including an order parameter plot. Illustrated in the plot is the breaking and reforming of
hydrogen bonds per layer (5’ Face/Red, Top G-Tetrad/Cyan, Middle G-Tetrad /Blue, Bottom G-Tetrad
/Black, and 3’ Face/Green), drug-base dihedral angle, ligand(black)/DNA(red) RMSD (Å) with reference to
the final structure, ligand center to DNA center distance(black) and K+ to K+ distance(red), and the MMGBSA binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and blue ball,
respectively. K+ ions are indicated by yellow balls.

222

00 ns

27 ns

62 ns

146 ns

Figure B23. Snapshots from the representative trajectory of the top binding mode of the c-Myc G4, run 10,
including an order parameter plot. Illustrated in the plot is the breaking and reforming of hydrogen bonds
per layer (5’ Face/Red, Top G-Tetrad/Cyan, Middle G-Tetrad /Blue, Bottom G-Tetrad /Black, and 3’
Face/Green), drug-base dihedral angle, ligand(black)/DNA(red) RMSD (Å) with reference to the final
structure, ligand center to DNA center distance(black) and K+ to K+ distance(red), and the MM-GBSA
binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and blue ball,
respectively. K+ ions are indicated by yellow balls.
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Figure B24. Snapshots from the representative trajectory of the bottom binding mode of c-Myc G4, run 25,
including an order parameter plot. Illustrated in the plot is the breaking and reforming of hydrogen bonds
per layer (5’ Face/Red, Top G-Tetrad/Cyan, Middle G-Tetrad /Blue, Bottom G-Tetrad /Black, and 3’
Face/Green), drug-base dihedral angle, ligand(black)/DNA(red) RMSD (Å) with reference to the final
structure, ligand center to DNA center distance(black) and K+ to K+ distance(red), and the MM-GBSA
binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and blue ball,
respectively. K+ ions are indicated by yellow balls.
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Figure B25. Snapshots from the representative trajectory of the bottom binding mode of
c-Myc G4, run 27, including an order parameter plot. Illustrated in the plot is the
breaking and reforming of hydrogen bonds per layer (5’ Face/Red, Top G-Tetrad/Cyan,
Middle G-Tetrad /Blue, Bottom G-Tetrad /Black, and 3’ Face/Green), drug-base dihedral
angle, ligand(black)/DNA(red) RMSD (Å) with reference to the final structure, ligand
center to DNA center distance(black) and K+ to K+ distance(red), and the MM-GBSA
binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and
blue ball, respectively. K+ ions are indicated by yellow balls.
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Figure B26. Snapshots from the representative trajectory of the side binding intermediate mode of the cMyc G4, run 17, including an order parameter plot. Illustrated in the plot is the breaking and reforming of
hydrogen bonds per layer (5’ Face/Red, Top G-Tetrad/Cyan, Middle G-Tetrad /Blue, Bottom G-Tetrad
/Black, and 3’ Face/Green), drug-base dihedral angle, ligand(black)/DNA(red) RMSD (Å) with reference to
the final structure, ligand center to DNA center distance(black) and K+ to K+ distance(red), and the MMGBSA binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and blue ball,
respectively. K+ ions are indicated by yellow balls.
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Figure B27. Snapshots from the representative trajectory of the duplex DNA system, run 14, including an
order parameter plot. Illustrated in the plot is the ligand(black)/DNA(red) RMSD (Å) with reference to the
final structure, ligand center to DNA center distance(black) and the MM-GBSA binding energy (ΔE in
kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red and blue ball, respectively. K+ ions are
indicated by yellow balls.
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Figure B28. Snapshots from the representative trajectory of the duplex DNA system, run 06,
including an order parameter plot. Illustrated in the plot is the ligand(black)/DNA(red) RMSD
(Å) with reference to the final structure, ligand center to DNA center distance(black) and the
MM-GBSA binding energy (ΔE in kcal/mol) . 5’ and 3’ of the DNA chain are indicated by a red
and blue ball, respectively. K+ ions are indicated by yellow balls.
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Figure B29. Snapshots from the representative trajectory of the duplex DNA system, run
25, including an order parameter plot. Illustrated in the plot is the
ligand(black)/DNA(red) RMSD (Å) with reference to the final structure, ligand center to
DNA center distance(black) and the MM-GBSA binding energy (ΔE in kcal/mol) . 5’ and
3’ of the DNA chain are indicated by a red and blue ball, respectively. K+ ions are
indicated by yellow balls.
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Figure B30. Hydrogen bond network of each layer formed by the human telomeric Gquadruplex in each representative binding modes.
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Figure B31. Hydrogen bond network of each layer formed by the c-KIT1 promoter Gquadruplex in each representative binding modes.
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Figure B32. Hydrogen bond network of each layer formed by the c-Myc G-quadruplex in
each representative binding modes.

232

CX-5461
QQ58
Figure B33. Comparison of CX-5461 and structurally related ligand QQ58.
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Chemical Structure

Duplex

RHPS4

CX-5461
Figure B34. Comparison between RHPS4 and CX-5461.
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Chemical Structure of CX-5461: Substitution
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Docking Score
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Duplex: -5.944
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Chemical Structure of New Ligand
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Docking Score
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c-KIT1: -7.514
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Figure B35. Chemical structure of CX-5461 and additional derivates identified through
virtual screening, including docking scores. For CX-5461 green arrows indicate
substitution sites for the derivates on this table. For the derivates, docking scores are
provided as well as the difference between their docking scores and CX-5461.
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Figure B36. AMBER GAFF2 force field of the ligand CX-5461 (+1) in Mol2 format.
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